register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01059123 | [
{
"id_field": "org_study_id",
"id_value": [
"P071207"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2008-006794-32"
]
},
{
"id_field": "acronym",
"id_value": [
"SHARE"
]
}
] | https://clinicaltrials.gov/study/NCT01059123 | Short Course of Amoxicillin for Erysipelas | The propose of this study is to determine whether a 6-day duration of oral amoxicillin treatment of erysipelas is non-inferior to a 14-day standard duration intravenous then oral amoxicillin regimen. This trial will be open but evaluation will be perform by a blind evaluator. | Randomized Non Inferiority Study Comparing Short Course of Oral Amoxicillin to One of the Usual Treatments of Lower Leg Erysipelas | [
{
"description": "50 mg/kg/24H ; Per Os ; 3 times/day 6 days",
"name": "Amoxicillin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to da... | [
{
"design_group_description": "amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.",
"design_group_title": "1:Short treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_descript... | [
"Erysipelas"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"Société Française de Dermatologie"
] | [
[
{
"name": "阿莫西林钠",
"lang": "CN"
},
{
"name": "Amoxicillin Sodium",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SHARE"
}
] |
NCT01056497 | [
{
"id_field": "org_study_id",
"id_value": [
"090818B"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Canadian Diabetes Association"
]
}
] | https://clinicaltrials.gov/study/NCT01056497 | The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion | Chronically elevated free fatty acids impair insulin sensitivity and insulin secretion (ie lipotoxicity) by a combination of oxidative stress, endoplasmic reticulum (ER) stress and inflammation. This study will test whether alpha-lipoic acid, which has potent antioxidant and anti-inflammatory properties, prevents or am... | The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion | [
{
"description": "A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will inges... | [
{
"design_group_title": "alpha lipoic acid",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "A 2 week treatment period with either oral ALA tablets or placebo tablets, followed ... | [
"Type 2 Diabetes",
"Prediabetes"
] | [
"University Health Network"
] | [
"Diabetes Canada"
] | [
[
{
"name": "硫辛酸",
"lang": "CN"
},
{
"name": "Lipoic acid",
"lang": "EN"
}
]
] | null |
NCT03544268 | [
{
"id_field": "org_study_id",
"id_value": [
"LCCC1748"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01CA189479-01"
]
}
] | https://clinicaltrials.gov/study/NCT03544268 | Academic-Industrial Partnership for Translation of Acoustic Angiography | Purpose: The primary objective of this single arm study is to compare the sensitivity and specificity of acoustic angiography with traditional b-mode ultrasound in the distinction of malignant versus benign breast lesions. Secondary objectives include a comparison of area under the curve (AUC) for acoustic angiography ... | Academic-Industrial Partnership for Translation of Acoustic Angiography | [
{
"description": "Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. T... | [
{
"design_group_description": "All clinical patients will be included in the experimental group.",
"design_group_title": "Acoustic Angiography",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interven... | [
"Signs and Symptoms"
] | [
"Lineberger Comprehensive Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "全氟丙烷脂质微球",
"lang": "CN"
},
{
"name": "Perflutren lipid microsphere",
"lang": "EN"
}
]
] | null |
NCT04484259 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB202001694"
]
},
{
"id_field": "acronym",
"id_value": [
"OPTIMUS-7"
]
}
] | https://clinicaltrials.gov/study/NCT04484259 | Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus | Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm. Such effects have shown to of particular benefit in patients with diabetes mellitus (DM). However, if an aspirin-f... | Pharmacodynamic Effects of Different Ticagrelor Maintenance Dosing Regimens With and Without Aspirin in Patients With Diabetes Mellitus: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-7 Study | [
{
"description": "Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequen... | [
{
"design_group_description": "ticagrelor 60 mg bid monotherapy",
"design_group_title": "Ticagrelor",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Eligible patients will ... | [
"Diabetes Mellitus, Type 2",
"Coronary Artery Disease"
] | [
"University of Florida"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "替格瑞洛",
"lang": "CN"
},
{
"name": "Ticagrelor",
"lang": "EN"
},
{
"name": "チカグレロル",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "52a3842a88022e905584224a0ed22024",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "OPTIMUS-7"
}
] |
NCT00296023 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000463724"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCSF-98251"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCSF-9805"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCS... | https://clinicaltrials.gov/study/NCT00296023 | Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immu... | Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies | [
{
"name": "anti-thymocyte globulin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "filgrastim",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "therapeutic allogeneic lymphocytes",
"normaliz... | [
{
"design_group_title": "stem cell transplant",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "therapeutic allogeneic lymphocytes",
"intervention_type": "Biological",
... | [
"Chronic Myeloproliferative Disorders",
"Leukemia",
"Lymphoma",
"Multiple Myeloma and Plasma Cell Neoplasm",
"Myelodysplastic Syndromes"
] | [
"The University of California, San Francisco"
] | [
"National Cancer Institute"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT07363954 | [
{
"id_field": "org_study_id",
"id_value": [
"STR-P004-005"
]
},
{
"id_field": "secondary_id",
"id_value": [
"STR-P004-005"
]
}
] | https://clinicaltrials.gov/study/NCT07363954 | To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney Diseases | This is a single-center, non-randomized, open-label, single-arm exploratory clinical study, using Bayesian Optimal Interval (BOIN) design. Three dose groups are planned: DL1 XX mg/kg, DL2 XXmg/kg, DL3 XXmg/kg. Starting dose is XX mg/kg. Each treatment cycle is 28 days, with 4 infusions on D1, D4, D7, D10; 1-2 cycles. T... | A Clinical Study on the Safety, Efficacy, and Pharmacokinetics of STR-P004 for the Treatment of Immune-Mediated Kidney Diseases | [
{
"description": "Three dose groups are planned: DL1 XXmg/kg, DL2 XXmg/kg, DL3 XX mg/kg. Starting dose is XX mg/kg.",
"name": "STR-P004 dose group",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Dose1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Three dose groups are planned: DL1 XXmg/kg, DL2 XXmg/kg, DL3 XX mg/kg. Starting dose is XX mg/kg... | [
"Autoimmune Diseases"
] | [
"Starna therapeutics"
] | [
"Zhongshan Hospital Fudan University"
] | [
[
{
"name": "STR-P004",
"lang": "EN"
}
]
] | null |
NCT00655980 | [
{
"id_field": "org_study_id",
"id_value": [
"HSC 07-0592"
]
},
{
"id_field": "acronym",
"id_value": [
"VINO"
]
}
] | https://clinicaltrials.gov/study/NCT00655980 | Vitamins in Nitrous Oxide Study | In this study, we want to find out if laughing gas (nitrous oxide) leads to a higher rate of cardiac complications after surgery in patients with a specific genetic profile (mutations in the MTHFR gene) and if this risk can be prevented by giving patients vitamin B12 and folate during surgery. | Pharmacogenetics of Adverse Outcomes After Nitrous Oxide Anesthesia | [
{
"description": "1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion",
"name": "Vitamin B12 and folic acid",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Nitrous oxide and placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Vitamin B12 and folic acid",
"design_group_title": "Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "1 mg vitamin B12 IV 5 mg folic... | [
"Major Surgery",
"Coronary Artery Disease"
] | [
"Washington University School of Medicine"
] | [
"National Institute of General Medical Sciences",
"Foundation For Anesthesia Education & Research"
] | [
[
{
"name": "盐酸硫胺素",
"lang": "CN"
},
{
"name": "Thiamine Hydrochloride",
"lang": "EN"
},
{
"name": "チアミン塩化物塩酸塩",
"lang": "JP"
}
],
[
{
"name": "叶酸",
"lang": "CN"
},
{
"name": "Folic Acid",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "58284422d884a2eda25e29d55292d028",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "VINO"
}
] |
NCT01404871 | [
{
"id_field": "org_study_id",
"id_value": [
"OCF-Richter"
]
}
] | https://clinicaltrials.gov/study/NCT01404871 | Predicting Medication Response in Obsessive Compulsive Disorder | In this study, the investigators hope to study a number of variables the investigators believe may help us predict why some people respond better to some medications than others. Participants will be randomly assigned to receive one of two typical medications for OCD, clomipramine or escitalopram. Individuals who would... | Predicting Medication Response in Obsessive Compulsive Disorder | [
{
"description": "oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily",
"name": "clomipramine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Anafranil"
],
"type": "Drug"
},
{
"description": "oral tablet, starting 10mg... | [
{
"design_group_description": "Randomized trial of clomipramine or escitalopram",
"design_group_title": "Randomization to ECIT or CMI",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention... | [
"Obsessive Compulsive Disorder"
] | [
"Sunnybrook Health Sciences Centre"
] | [
"Centre for Addiction & Mental Health",
"Obsessive-Compulsive Foundation"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸度洛西汀",
"lang": "CN"
},
{
"name": "Duloxetine Hydrochloride",
"lang... | null |
NCT04121728 | [
{
"id_field": "org_study_id",
"id_value": [
"2018-02134 BASEC"
]
},
{
"id_field": "acronym",
"id_value": [
"AgilGinkgo"
]
}
] | https://clinicaltrials.gov/study/NCT04121728 | Modulation of Attention in Event Related Potential (ERPs) as a Marker of Early Cognitive Decline by Ginkgo Biloba | The objective of this study is to simultaneously establish the metrological characteristics of the new executive function markers (decision making and multiple flow management) derived from repeated ERP variations and to identify their ability to test whether a short treatment using Ginkgo biloba versus placebo extract... | Evaluation of the Modulation of Attention Explored in ERPs as a Marker of Early Cognitive Decline: Concept Validation on the Effect of Ginkgo Biloba Extracts. Randomized, Double-blind, Cross-over, Placebo-controlled Study | [
{
"description": "Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.",
"name": "Ginkgo biloba extract",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Symfona®"
],
"type": "Dru... | [
{
"design_group_description": "Cross-over design: In Group Ginkgo-Placebo participants are allocated first to the IMP Symfona® during 6 months and after 2 months of wash-out period are allocated to the placebo for 6 months.",
"design_group_title": "Group Ginkgo-Placebo",
"design_group_type": "Other",
... | [
"Subjective Cognitive Decline",
"Cognitive Performance",
"Functional Capacity",
"Age-related Cognitive Decline"
] | [
"Centre Hospitalier Universitaire Vaudois"
] | [
"Centre Hospitalier Universitaire Vaudois"
] | [
[
{
"name": "银杏叶提取物",
"lang": "CN"
},
{
"name": "Extract of Ginkgo Biloba Leaves",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AgilGinkgo"
}
] |
NCT03000075 | [
{
"id_field": "org_study_id",
"id_value": [
"M16-004"
]
},
{
"id_domain": "Boehringer Ingelheim",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"1311.38"
]
}
] | https://clinicaltrials.gov/study/NCT03000075 | BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis | This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab). | A Phase II/III, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Two Different Dose Regimens of BI 655066 (Risankizumab) and Placebo and Maintenance of Response of BI 655066 (Risankizumab) Administered Subcutaneously in Japanese Patients With Moderate to Severe Chronic Plaque Type Psoriasis. | [
{
"description": "Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection",
"name": "risankizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ABBV-066",
"BI 655066"
],
"type": "Drug"
},
{
"description": "Placebo for risan... | [
{
"design_group_description": "Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).",
"design_group_title": "Placebo (Part A)",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d9... | [
"Psoriasis"
] | [
"AbbVie, Inc."
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "利生奇珠单抗",
"lang": "CN"
},
{
"name": "Risankizumab-RZAA",
"lang": "EN"
},
{
"name": "リサンキズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "52a9488845e54a9828e05a2a22ea353a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "ae9d8382a2a8d445ea8edd222eed4de2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Sus... |
NCT05913661 | [
{
"id_field": "org_study_id",
"id_value": [
"SYSKY-2023-061-01"
]
}
] | https://clinicaltrials.gov/study/NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma. | Prospective, Single-arm, Multicenter Phase II Study of Evaluation of the Efficacy and Safety of Pemigatinib Combined With PD-1 Inhibitor in First-line Treatment of Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | [
{
"description": "Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.",
"name": "Pemigatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Pemazyre"
],
"type": "Drug"
... | [
{
"design_group_description": "pemigatinib combined with PD-1 inhibitor as first-line treatment within advanced unresectable or metastatic intrahepatic cholangiocarcinoma",
"design_group_title": "pemigatinib combined with PD-1 inhibitor",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Carcinoma",
"Intrahepatic Cholangiocarcinoma",
"Digestive System Neoplasms",
"PD-1 Inhibitor",
"First-line Treatment"
] | [
"Sun Yat-Sen Memorial Hospital"
] | [
"The First Affiliated Hospital of Jinan University"
] | [
[
{
"name": "信迪利单抗",
"lang": "CN"
},
{
"name": "Sintilimab",
"lang": "EN"
}
],
[
{
"name": "佩米替尼",
"lang": "CN"
},
{
"name": "Pemigatinib",
"lang": "EN"
},
{
"name": "ペミガチニブ",
"lang": "JP"
}
]
] | null |
NCT00003966 | [
{
"id_field": "org_study_id",
"id_value": [
"99118"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA015704"
]
},
{
"id_field": "secondary_id",
"id_value": [
"DFCI-1999-P-010076/14"
]
},
{
"id_field... | https://clinicaltrials.gov/study/NCT00003966 | Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation | RATIONALE: Giving defibrotide may be an effective treatment for liver damage that may result following peripheral stem cell transplantation.<br/>PURPOSE: This randomized phase II trial is studying defibrotide to see how well it works in treating patients with severe liver disease after undergoing peripheral stem cell t... | Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose | [
{
"name": "defibrotide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Defitelio®"
],
"type": "Drug"
}
] | [
{
"design_group_description": "This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.<br/>- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV... | [
"Veno-occlusive Disease"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"National Cancer Institute",
"Jazz Pharmaceuticals Plc"
] | [
[
{
"name": "去纤苷钠",
"lang": "CN"
},
{
"name": "Defibrotide Sodium",
"lang": "EN"
},
{
"name": "デフィブロチドナトリウム",
"lang": "JP"
}
]
] | null |
NCT00321802 | [
{
"id_field": "org_study_id",
"id_value": [
"18108"
]
},
{
"id_field": "acronym",
"id_value": [
"PAFRIOSIES"
]
}
] | https://clinicaltrials.gov/study/NCT00321802 | Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins | The purpose of this study is to determine the effect of statin therapy for prevention of atrial fibrillation (AF) in pacemaker and non-pacemaker patients with paroxysmal atrial fibrillation in the absence of significant coronary artery disease. | Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins | [
{
"description": "Patients take 40 mg of simvastatin per day for 6 months.",
"name": "Simvastatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Zocor"
],
"type": "Drug"
},
{
"description": "Placebo",
"name": "Placebo",
"normalized_type": "3d1... | [
{
"design_group_description": "Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Atrial Fibrillation"
] | [
"University of Calgary"
] | [
"Merck Sharp & Dohme Corp.",
"Canadian Institutes of Health Research"
] | [
[
{
"name": "辛伐他汀",
"lang": "CN"
},
{
"name": "Simvastatin",
"lang": "EN"
},
{
"name": "シンバスタチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PAFRIOSIES"
}
] |
NCT00068341 | [
{
"id_field": "org_study_id",
"id_value": [
"99-11-084"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CDR0000321924"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AVENTIS-GIA-11156"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00068341 | Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer | RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It... | Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer | [
{
"description": "Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV",
"name": "trastuzumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Herceptin"
],
"type": "Biological"
},
{
"descrip... | [
{
"design_group_description": "see intervention description",
"design_group_title": "Arm I (neoadjuvant therapy)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Cycle 1-8 ... | [
"Breast Cancer"
] | [
"Jonsson Comprehensive Cancer Center"
] | [
"Genentech, Inc.",
"Aventis Pharmaceuticals, Inc."
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
... | null |
NCT06036602 | [
{
"id_field": "org_study_id",
"id_value": [
"Sabin-003"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Sabin-003"
]
}
] | https://clinicaltrials.gov/study/NCT06036602 | Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults | A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults | [
{
"description": "The recombinant chimpanzee adenovirus Type 3-vectored Sudan Ebolavirus vaccine, (cAd3-EBO S) is composed of a cAd3 vector that expresses wild type glycoprotein (WT GP) from the Sudan Gulu ebolavirus strain.",
"name": "cAD3-Sudan Ebolavirus Vaccine",
"normalized_type": "30faef638ae74cc7... | [
{
"design_group_description": "Single dose of cAd3-Sudan Ebolavirus vaccine (1x10^11 PU) administered intramuscularly (IM) with needle and syringe.",
"design_group_title": "cAD3-Sudan Ebolavirus Vaccine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f... | [
"Ebola Sudan Virus Disease"
] | [
"Albert B. Sabin Vaccine Institute, Inc."
] | [
"Biomedical Advanced Research & Development Authority (Barda)"
] | [
[
{
"name": "Ebola Sudan vaccine(Albert B. Sabin Vaccine Institute)",
"lang": "EN"
}
]
] | null |
NCT04715763 | [
{
"id_field": "org_study_id",
"id_value": [
"H053"
]
},
{
"id_field": "acronym",
"id_value": [
"INTEL"
]
}
] | https://clinicaltrials.gov/study/NCT04715763 | INvestigating TELmisartin Study | This study will enroll 40 inpatients hospitalized for COVID-19 at Queens' Medical Center. Participants will be randomized 1:1 to Telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days. | Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Treatment of COVID-19 in Hospitalized Patients | [
{
"description": "Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction",
"name": "Telmisartan Oral Product",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Micardis"
],
"type": "Drug"
},
{
"descri... | [
{
"design_group_description": "Telmisartan 80 mg (given as two 40 mg encapsulated tablets) given orally each day x 21 days",
"design_group_title": "Telmisartan (80 mg)",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention... | [
"Covid19"
] | [
"University of Hawaii System"
] | [
"The Queen's Medical Center"
] | [
[
{
"name": "替米沙坦",
"lang": "CN"
},
{
"name": "Telmisartan",
"lang": "EN"
},
{
"name": "テルミサルタン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "INTEL"
}
] |
NCT00349921 | [
{
"id_field": "org_study_id",
"id_value": [
"P01NS041386_TRIAL1"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P01NS041386"
]
}
] | https://clinicaltrials.gov/study/NCT00349921 | Clonidine Versus Adenosine to Treat Neuropathic Pain | The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain. | Clonidine Versus Adenosine to Treat Neuropathic Pain | [
{
"description": "Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into th... | [
{
"design_group_description": "clonidine given in first injection adenosine given in second injection",
"design_group_title": "clonidine first, then adenosine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Pain"
] | [
"Wake Forest School of Medicine"
] | [
"National Institute of Neurological Disorders & Stroke"
] | [
[
{
"name": "盐酸可乐定",
"lang": "CN"
},
{
"name": "Clonidine Hydrochloride",
"lang": "EN"
},
{
"name": "クロニジン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "腺苷",
"lang": "CN"
},
{
"name": "Adenosine",
"lang": "EN"
},
{
... | null |
NCT01948128 | [
{
"id_field": "org_study_id",
"id_value": [
"20120362-2OH"
]
},
{
"id_field": "acronym",
"id_value": [
"OTT 12-06"
]
}
] | https://clinicaltrials.gov/study/NCT01948128 | Effects of Vitamin D in Patients With Breast Cancer | This protocol is a randomized, phase 2 "window of opportunity" trial assessing the biological effects of short term oral vitamin D administration on breast cancer clinical and translational markers in patients awaiting surgery at the Ottawa Hospital. It takes advantage of the current wait times (2-8 weeks) for breast c... | A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Vitamin D in Patients With Breast Cancer. The ICARUS Trial | [
{
"description": "Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.",
"name": "Vitamin D3",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Vitamin D",
"cholecalciferol"
],
... | [
{
"design_group_description": "Vitamin D3 40,000 iu per day by mouth",
"design_group_title": "Vitamin D3",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants will ... | [
"Breast Cancer"
] | [
"Ottawa Hospital Research Institute"
] | [
"The Canadian Breast Cancer Foundation"
] | [
[
{
"name": "维生素D3",
"lang": "CN"
},
{
"name": "Colecalciferol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "OTT 12-06"
}
] |
NCT04483115 | [
{
"id_field": "org_study_id",
"id_value": [
"TPN171H-P201"
]
}
] | https://clinicaltrials.gov/study/NCT04483115 | Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension | This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo group and the test drugs... | Multi-center, Randomized，Placebo and Positive Controlled Clinical Study of TPN171H Tablets on Acute Haemodynamics in Patients with Pulmonary Arterial Hypertension | [
{
"description": "Tablets; Oral; Single dose",
"name": "TPN171H",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Simmerafil"
],
"type": "Drug"
},
{
"description": "Tablets; Oral; Single dose",
"name": "Placebo",
"normalized_type": "3d1aa88261d64... | [
{
"design_group_description": "TPN171H 2.5mg tablet + Placebo 10mg tablet",
"design_group_title": "TPN171H 2.5mg group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Tabl... | [
"Pulmonary Arterial Hypertension"
] | [
"Suzhou Vigonvita Life Sciences Co.,Ltd"
] | [
"Shanghai Institute of Materia Medica Chinese Academy of Sci"
] | [
[
{
"name": "盐酸司美那非",
"lang": "CN"
},
{
"name": "Simenafil Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT02248597 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00029210"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-01898"
]
},
{
"id_domain": "Comprehensive Cancer Cent... | https://clinicaltrials.gov/study/NCT02248597 | Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases | This pilot clinical trial studies donor stem cell transplant followed by cyclophosphamide in treating patients with hematological diseases. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When ... | Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study | [
{
"description": "Given IV",
"name": "fludarabine phosphate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"2-F-ara-AMP",
"Beneflur",
"Fludara"
],
"type": "Drug"
},
{
"description": "Given IV",
"name": "busulfan",
"normalized_type":... | [
{
"design_group_description": "PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours... | [
"Graft Versus Host Disease",
"Hematopoietic/Lymphoid Cancer"
] | [
"Wake Forest School of Medicine"
] | [
"National Cancer Institute"
] | [
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT07412171 | [
{
"id_field": "org_study_id",
"id_value": [
"LM2026029"
]
},
{
"id_domain": "Peking University Third Hospital Medical Science Research Ethics Committee",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"IRB00006761"
]
},
{
"id_domain":... | https://clinicaltrials.gov/study/NCT07412171 | NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC | The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).<br/>In this study, eligible participants will be randomly assigned to receive either neoadjuvant treatment with tori... | NECTAR Study: A Multicenter, Open-label, Randomized Phase II Study of Neoadjuvant Toripalimab Plus 9MW2821 Versus Upfront Radical Nephroureterectomy With/Without Lymph Node Dissection in Patients With Local Upper Tract Urothelial Carcinoma (UTUC) | [
{
"description": "Toripalimab is administered intravenously at a dose of 240 mg every 3 weeks for 3 cycles as neoadjuvant therapy prior to surgery.",
"name": "Toripalimab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "9MW2821 is administered intr... | [
{
"design_group_description": "Participants receive neoadjuvant toripalimab plus 9MW2821 followed by radical nephroureterectomy with or without lymph node dissection.",
"design_group_title": "Neoadjuvant Toripalimab + 9MW2821",
"design_group_type": "Experimental",
"design_group_type_normalized_id": ... | [
"Upper Tract Urothelial Carcinoma"
] | [
"Peking University Third Hospital"
] | [
"Beijing Tumor Hospital",
"Beijing Friendship Hospital",
"The First Affiliated Hospital of Zhengzhou University",
"Jiangsu Provincial People's Hospital"
] | [
[
{
"name": "特瑞普利单抗",
"lang": "CN"
},
{
"name": "Toripalimab",
"lang": "EN"
}
],
[
{
"name": "Bulumtatug fuvedotin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "NECTAR"
}
] |
NCT00242333 | [
{
"id_field": "org_study_id",
"id_value": [
"P-AD237-005"
]
}
] | https://clinicaltrials.gov/study/NCT00242333 | A Study to Assess the Safety and Efficacy of Different AD 237 Doses in Adults With COPD | The purpose of this study is to investigate the efficacy, safety and tolerability of AD 237 in patients with chronic obstructive pulmonary disease (COPD). | A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD. | [
{
"name": "AD 237",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"COPD"
] | [
"Sosei Co. Ltd."
] | [
"Novartis AG"
] | [
[
{
"name": "格隆溴铵",
"lang": "CN"
},
{
"name": "Glycopyrrolate",
"lang": "EN"
},
{
"name": "グリコピロニウム臭化物",
"lang": "JP"
}
]
] | null |
NCT01910246 | [
{
"id_field": "org_study_id",
"id_value": [
"MetforminMRI"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Cardiac MRI Metformin"
]
},
{
"id_domain": "UCSF",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"Metformin Cardia... | https://clinicaltrials.gov/study/NCT01910246 | Cardiovascular Effects of Metformin on Obesity | It has been shown that asymptomatic obese adolescents can demonstrate abnormal regional myocardial contraction, with preserved global cardiac function. Metformin has been shown to decrease cardiovascular mortality in patients with type 2 diabetes and insulin resistance, but the mechanism of cardiovascular protection is... | Cardiovascular Effects of Metformin on Obesity With Subclinical Myocardial Dysfunction | [
{
"name": "Metformin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.",
"design_group_title": "Metformin, Insulin Resistance, Cardiac Function,",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b3544... | [
"Insulin Resistance"
] | [
"The University of California, San Francisco"
] | [
"US Department of Veterans Affairs (District of Columbia)"
] | [
[
{
"name": "盐酸二甲双胍",
"lang": "CN"
},
{
"name": "Metformin Hydrochloride",
"lang": "EN"
},
{
"name": "メトホルミン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT04743622 | [
{
"id_field": "org_study_id",
"id_value": [
"MIT 2019-02-020"
]
}
] | https://clinicaltrials.gov/study/NCT04743622 | Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost | Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study | Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients | [
{
"description": "preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes",
"name": "Monoprost",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Preservative-free latanoprost"
],
"type": "Drug"
},
{
"description": "preserved latanopro... | [
{
"design_group_description": "latanoprost : 1 drop once a day for 12 weeks to target eyes",
"design_group_title": "Monoprost (preservative-free latanoprost eye drop)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Glaucoma",
"Ocular Hypertension"
] | [
"CHA University"
] | [
"SAMIL PHARMACEUTICAL Co., Ltd."
] | [
[
{
"name": "拉坦前列素",
"lang": "CN"
},
{
"name": "Latanoprost",
"lang": "EN"
},
{
"name": "ラタノプロスト",
"lang": "JP"
}
]
] | null |
NCT00516113 | [
{
"id_field": "org_study_id",
"id_value": [
"L&E-5"
]
}
] | https://clinicaltrials.gov/study/NCT00516113 | A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria | The objective of this study is to explore the onset of action when serotonin reuptake inhibitors are used to treat premenstrual dysphoric disorder | A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine When Used for the Treatment of Premenstrual Dysphoria | [
{
"description": "Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM",
"name": "paroxetine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Paroxetine 20mg during the luteal phase of the menstrual cycle",
"design_group_title": "1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description"... | [
"Premenstrual Dysphoric Disorder",
"Premenstrual Syndrome"
] | [
"Karolinska Institutet"
] | [
"GSK Plc",
"Novo Nordisk A/S",
"University of Gothenburg"
] | [
[
{
"name": "盐酸帕罗西汀",
"lang": "CN"
},
{
"name": "Paroxetine Hydrochloride",
"lang": "EN"
},
{
"name": "パロキセチン塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT00281606 | [
{
"id_field": "org_study_id",
"id_value": [
"CCTG 585"
]
}
] | https://clinicaltrials.gov/study/NCT00281606 | A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules | Guidelines have continued to list lopinavir/ritonavir as a preferred protease inhibitor-containing regimen for HIV-infected individuals. There has recently been increasing interest in once daily therapy. While lopinavir/ritonavir has recently been approved as a once daily therapy it was associated with considerable dia... | A Phase IV, Randomized, Open-label Study of the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules | [
{
"description": "CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules",
"name": "Different formulations of once-daily lopinavir/ritonavir",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"L... | [
{
"design_group_description": "Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid",
"design_group_title": "LPV/r (800/200 mg) 10 ml liquid",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{... | [
"HIV Infection"
] | [
"University of California San Diego"
] | [
"Abbott Laboratories"
] | [
[
{
"name": "洛匹那韦/利托那韦",
"lang": "CN"
},
{
"name": "Lopinavir/Ritonavir",
"lang": "EN"
},
{
"name": "ロピナビル/リトナビル",
"lang": "JP"
}
]
] | null |
NCT02753283 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY19050268"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1R01AG052123-01"
]
},
{
"id_field": "acronym",
"id_value": [
"PROUD"
]
}
] | https://clinicaltrials.gov/study/NCT02753283 | Preventing Osteoporosis Using Denosumab | The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and older) who have osteoporosis and reside in long-term care (LTC) facilities. | Sustaining Skeletal Health in Frail Elderly | [
{
"description": "Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)",
"name": "denosumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Prolia"
],
"type": "Drug"
},
{
"descrip... | [
{
"design_group_description": "Semi-annual dose for women: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements).",
"design_group_title": "Women Denosumab",
"design_group_type": "Experimental",
"design_group_type_normalized... | [
"Osteoporosis, Postmenopausal",
"Osteoporosis",
"Osteoporotic Fractures"
] | [
"University of Pittsburgh"
] | [
"National Institute on Aging",
"National Institutes of Health"
] | [
[
{
"name": "地舒单抗",
"lang": "CN"
},
{
"name": "Denosumab",
"lang": "EN"
},
{
"name": "デノスマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "2e5e54220528e858882eaed552ed8585",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PROUD"
}
] |
NCT04582305 | [
{
"id_field": "org_study_id",
"id_value": [
"BLEO JET"
]
}
] | https://clinicaltrials.gov/study/NCT04582305 | Bleomycin Jet Injections in Keloids | This is a single center, double-blind (patient and investigator), randomized, placebo-controlled study with a split-lesion design, in which selected keloids will receive three consecutive treatments of a) bleomycin and b) placebo (saline (NaCl 0,9%)), administered with an electronic pneumatic jet injector. | Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design | [
{
"description": "Intralesional bleomycin treatment administered with an electronic pneumatic jet injector",
"name": "Bleomycin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intralesional placebo treatment of normal saline administered with an e... | [
{
"design_group_description": "This study consists of a split-lesion design in which the keloid scar will receive three consecutive treatments with an interval of 4 weeks of: 1) bleomycin and 2) placebo (NaCl 0,9%), administered with an electronic pneumatic jet injector. A single injection of 100 μL will be giv... | [
"Keloid"
] | [
"Erasmus Universitair Medisch Centrum Rotterdam"
] | [
"Centre for Human Drug Research"
] | [
[
{
"name": "盐酸博莱霉素",
"lang": "CN"
},
{
"name": "Bleomycin Hydrochloride",
"lang": "EN"
},
{
"name": "ブレオマイシン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT03826199 | [
{
"id_field": "org_study_id",
"id_value": [
"K01TW011187"
]
},
{
"id_field": "acronym",
"id_value": [
"PrEP-PP"
]
}
] | https://clinicaltrials.gov/study/NCT03826199 | Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study) | The overarching goal of this proposal is to evaluate the feasibility and acceptability of integrating PrEP into antenatal and postnatal care, to describe the cascade in women initiating PrEP in this setting, and to evaluate the reasons for attrition along the PrEP cascade in a cohort of pregnant and breastfeeding women... | Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town, South Africa (Formative Study) | [
{
"description": "We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not... | null | [
"Hiv"
] | [
"University of California, Los Angeles"
] | [
"Desmond Tutu Hiv Foundation",
"University of Cape Town"
] | [
[
{
"name": "恩曲他滨替诺福韦",
"lang": "CN"
},
{
"name": "Emtricitabine/Tenofovir Disoproxil Fumarate",
"lang": "EN"
},
{
"name": "エムトリシタビン/テノホビル ジソプロキシルフマル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "PrEP-PP"
}
] |
NCT02585947 | [
{
"id_field": "org_study_id",
"id_value": [
"TenoCore"
]
}
] | https://clinicaltrials.gov/study/NCT02585947 | To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma | The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective pre... | A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy | [
{
"description": "Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).",
"... | [
{
"design_group_description": "* prophylactic (preemptive) treatment<br/>* 300mg for 24 weeks<br/>* once daily",
"design_group_title": "tenofovir for 24 weeks",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Non-Hodgkin's Lymphoma, Burkitt's"
] | [
"Seoul National University Hospital"
] | [
"Konkuk University Medical Center",
"Gilead Sciences, Inc."
] | [
[
{
"name": "替诺福韦",
"lang": "CN"
},
{
"name": "Tenofovir",
"lang": "EN"
}
]
] | null |
NCT03576677 | [
{
"id_field": "org_study_id",
"id_value": [
"RH-HJE-LN-02"
]
},
{
"id_field": "acronym",
"id_value": [
"LOCO-CHF"
]
}
] | https://clinicaltrials.gov/study/NCT03576677 | Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure | Purpose: This study evaluates the subacute effect of levosimendan infusion on exercise capacity and exercise hemodynamics compared with placebo in patients with advanced chronic heart failure.<br/>Hypothesis: Treatment with 6 hours infusion of levosimendan compared with placebo improves exercise capacity and exercise h... | Effect of Levosimendan or Placebo on Exercise Capacity and Hemodynamics in Patients With Advanced Chronic Heart Failure (LOCO-CHF Trial) | [
{
"description": "Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.<br/>Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min.",
"name": "Levosimendan",
"normalized_type": "3d1aa88... | [
{
"design_group_description": "Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.",
"design_group_title": "Levosimendan",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
... | [
"Heart Failure"
] | [
"Rigshospitalet"
] | [
"Orion Oyj"
] | [
[
{
"name": "左西孟旦",
"lang": "CN"
},
{
"name": "Levosimendan",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LOCO-CHF"
}
] |
NCT02638415 | [
{
"id_field": "org_study_id",
"id_value": [
"CSY-WYC02-2015"
]
}
] | https://clinicaltrials.gov/study/NCT02638415 | The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices | The purpose of the study is to compare the effect of HVPG-guided individualized therapy and non-HVPG guided traditional therapy in cirrhotic patients for secondary prophylaxis. | The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial | [
{
"description": "Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.<br/>Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.<br/>Patients ... | [
{
"design_group_description": "HVPG-guided therapy",
"design_group_title": "HVPG group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Patients in HVPG group with HVPG bel... | [
"Gastroesophageal Varices",
"Cirrhosis"
] | [
"Zhongshan Hospital Fudan University"
] | [
"Shanghai Public Health Clinical Center",
"Shuguang Hospital",
"Xinhua Hospital",
"Shanghai Eastern Hepatobiliary Surgery Hospital",
"Shanghai Pudong New District Gongli Hospital",
"Shanghai First People's Hospital"
] | [
[
{
"name": "卡维地洛",
"lang": "CN"
},
{
"name": "Carvedilol",
"lang": "EN"
},
{
"name": "カルベジロール",
"lang": "JP"
}
]
] | null |
NCT01936077 | [
{
"id_field": "org_study_id",
"id_value": [
"2010036"
]
},
{
"id_field": "acronym",
"id_value": [
"OPTOMALH"
]
}
] | https://clinicaltrials.gov/study/NCT01936077 | Severe LH Suppressed Patients After Administration of a GnRH Antagonist | The ideal stimulation protocol for ovarian stimulation is under constant debate, as we gain more pharmacological control over the patient hormonal milieu. Specifically, the debate focuses around the ideal LH levels. The concept of an "LH window" was suggested.<br/>The need for a threshold level of LH is clearly demonst... | To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist | [
{
"description": "150 IU recombinant LH daily.",
"name": "Recombinant LH (Luveris)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Luveris"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Those defined as hyper-responders will be given recombinant LH.",
"design_group_title": "GnRH antagomnist hyper-responders",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Infertility, Female Infertility, Male Infertility"
] | [
"Assuta Medical Centers Ltd."
] | [
"Maccabi Healthcare Services"
] | [
[
{
"name": "促黄体激素α",
"lang": "CN"
},
{
"name": "Lutropin Alfa",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "OPTOMALH"
}
] |
NCT06647342 | [
{
"id_field": "org_study_id",
"id_value": [
"CTIS: 2024-513360-25-00"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-513360-25-00"
]
},
{
"id_field": "acronym",
"id_value": [
"BLESS"
]
}
] | https://clinicaltrials.gov/study/NCT06647342 | The Effect of Reduced Bleomycin in Electrochemotherapy Treatment | The objective of this trial is to determine if reducing the chemotherapy dose in electrochemotherapy is equally effective as using the standard dose for treating various types of skin tumors.<br/>Electrochemotherapy involves administrating chemotherapy intravenously, followed shortly by a brief electrical pulse to the ... | Randomised Controlled Clinical Trial Investigating the Effect of Reduced Bleomycin in Elechtrochemotherapy Treatment on Patients with Cutaneous Malignancies (The BLESS Trial) | [
{
"description": "In the standard arm, Bleomycin (Baxter, Germany) at a dose of 15.000 IU/m² is used. In the dose reduction arm, a dose of 7500 IU/m² is used. Note that in Denmark bleomycin is dosed by international units, whereas other countries may use respectively U (units) or mg.",
"name": "Bleomycin",
... | [
{
"design_group_description": "Patients in this arm will recieve the standard dose of bleomycin during treatment with electrochemotherapy",
"design_group_title": "Standard dose",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"int... | [
"Cutaneous Metastasis",
"Cutaneous Malignant Mixed Tumor",
"Bleomycin Adverse Reaction",
"Electrochemotherapy"
] | [
"Zealand University Hospital"
] | [
"Herlev Hospital",
"Roskilde University"
] | [
[
{
"name": "盐酸博莱霉素",
"lang": "CN"
},
{
"name": "Bleomycin Hydrochloride",
"lang": "EN"
},
{
"name": "ブレオマイシン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "BLESS"
}
] |
NCT03615534 | [
{
"id_field": "org_study_id",
"id_value": [
"1 Al-KindyCM"
]
}
] | https://clinicaltrials.gov/study/NCT03615534 | Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females | Atherogenic Dyslipidemia (AD) is a risk-conferring lipid/lipoprotein profile that comprises a higher proportion of small LDL particles, reduced HDL-C, and increased triglycerides. It is characteristically seen in patients with obesity, metabolic syndrome, insulin resistance, and type 2 diabetes mellitus and has emerged... | Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females | [
{
"description": "Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.",
"name": "Therapeutic Lifestyle Changes",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"name": "Placebo"... | [
{
"design_group_description": "Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": ... | [
"Atherogenic Dyslipidemia",
"Obesity Associated Disorder"
] | [
"Al-Kindy College of Medicine"
] | [
"Al-Kindy College of Medicine"
] | [
[
{
"name": "非诺贝特",
"lang": "CN"
},
{
"name": "Fenofibrate",
"lang": "EN"
},
{
"name": "フェノフィブラート",
"lang": "JP"
}
]
] | null |
NCT05958875 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-506602-39-00 (EU CT#)"
]
},
{
"id_field": "acronym",
"id_value": [
"INTENSIFY SZ"
]
}
] | https://clinicaltrials.gov/study/NCT05958875 | The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. | Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros. The impact on the daily life of patients is huge, ranging from frequent relapses and hospitalisations, the inability to maintain a job or continue s... | A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. | [
{
"description": "Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.",
"name": "Clozapine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"ATC code: N05AH02"
],
"type"... | [
{
"design_group_description": "Subject with schizophrenia, randomized to EIPT: Switch to clozapine. Brand, dosage, frequency and duration up to the investigator's discretion",
"design_group_title": "Schizophrenia early intensified treatment (EIPT): Switch to clozapine",
"design_group_type": "Experimenta... | [
"Schizophrenia and Related Disorders",
"Early Treatment-Resistance"
] | [
"University Medical Center of Utrecht"
] | [
"Universität Leipzig"
] | [
[
{
"name": "氯氮平",
"lang": "CN"
},
{
"name": "Clozapine",
"lang": "EN"
},
{
"name": "クロザピン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "INTENSIFY SZ"
}
] |
NCT01356511 | [
{
"id_field": "org_study_id",
"id_value": [
"ITP-002"
]
}
] | https://clinicaltrials.gov/study/NCT01356511 | High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) | The project was undertaking by Qilu Hospital of Shandong University and other 11 well-known hospitals in China. In order to report the efficacy and safety of high-dose dexamethasone compared to conventional dose prednisone for the first-line treatment of adults with primary immune thrombocytopenia(ITP). | High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial | [
{
"description": "Prednisone, po, 1 mg/kg/d, for 4 weeks.",
"name": "Prednisone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"CD-PRE"
],
"type": "Drug"
},
{
"description": "Dexamethasone, po, 40 mg/d, for 4 days.",
"name": "Dexamethasone",
"n... | [
{
"design_group_description": "Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.",
"design_group_title": "Prednisone group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention":... | [
"Purpura, Thrombocytopenic, Idiopathic"
] | [
"Shandong University"
] | [
"Ruijin Hospital",
"Zhejiang Chinese Medicine Hospital",
"Shenzhen Second People's Hospital",
"Wuhan Xiehe Hospital Tower",
"Anhui Shackle Hospital Co., Ltd.",
"Second Hospital of Shanxi Medical University",
"Peking Union Medical College Hospital",
"Xinjiang Autonomous Region People's Hospital",
"Sh... | [
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
],
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "デキサメタゾンリン酸エステルナトリウム",
"lang":... | null |
NCT00137657 | [
{
"id_field": "org_study_id",
"id_value": [
"CDC-NCID-3354"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UR6/CCU018970-02-2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"SSC#664"
]
}
] | https://clinicaltrials.gov/study/NCT00137657 | Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance | At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis. Because of the demonstrated beneficial effect, high tolerability and low cost of CTX, the United Nations Programme... | An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli | [
{
"name": "Cotrimoxazole (trimethoprim sulfamethoxazole)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"HIV",
"Malaria",
"Diarrhea",
"Pneumonia",
"Opportunistic Infections"
] | [
"Centers for Disease Control & Prevention"
] | [
"Kenya Medical Research Institute"
] | [
[
{
"name": "磺胺甲噁唑/甲氧苄啶",
"lang": "CN"
},
{
"name": "Sulfamethoxazole/Trimethoprim",
"lang": "EN"
},
{
"name": "スルファメトキサゾール/トリメトプリム",
"lang": "JP"
}
]
] | null |
NCT00476164 | [
{
"id_field": "org_study_id",
"id_value": [
"2006-002330-38"
]
},
{
"id_field": "acronym",
"id_value": [
"RituxiCAN-C4"
]
}
] | https://clinicaltrials.gov/study/NCT00476164 | Study of Rituximab to Treat Chronic Renal Transplant Rejection | Purpose of clinical trial; Evaluate the effectiveness of rituximab in C4d+ CAN<br/>Primary objective; To determine whether anti-CD20 therapy can stabilize or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.<br/>Secondary ob... | Randomised Trial of Anti-Cd20 in C4d+ Chronic Allograft Nephropathy | [
{
"description": "2 doses of 1g 14 days apart",
"name": "Rituximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Mabthera"
],
"type": "Drug"
},
{
"description": "Continue of optimised oral immunosuppression",
"name": "Control arm",
"normalize... | [
{
"design_group_description": "Infusion of 2 x 1g of rituximab, 14 days apart",
"design_group_title": "Rituximab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "2 doses of... | [
"Kidney Transplantation",
"Graft Rejection",
"Immunosuppression"
] | [
"King's College London"
] | [
"Roche Pharma AG",
"The Medical Research Council"
] | [
[
{
"name": "利妥昔单抗",
"lang": "CN"
},
{
"name": "Rituximab",
"lang": "EN"
},
{
"name": "リツキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RituxiCAN-C4"
}
] |
NCT02859337 | [
{
"id_field": "org_study_id",
"id_value": [
"OHSU IRB 016291"
]
},
{
"id_field": "acronym",
"id_value": [
"UPA-Obesity"
]
}
] | https://clinicaltrials.gov/study/NCT02859337 | Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA | Obese women are significantly more likely than their normal BMI counterparts to experience failure of orally-dosed emergency contraceptives. Our preliminary data provides evidence for testing a dose escalation strategy in an effort to provide improved efficacy from orally-dosed emergency contraceptives in obese women. ... | Improving the Effectiveness of Orally Dosed Emergency Contraceptives in Obese Women - PK and PD of 30mg and 60mg UPA | [
{
"description": "Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC",
"name": "UPA-ECx1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ella",
"Ella-One"
],
"type": "Drug"
},
{
"description": "E... | [
{
"design_group_description": "Ulipristal acetate 30mg orally x 1 dose, washout cycle and then in the next menstrual cycle, 60mg x 1 dose. Timing of dosage depends on follicle measurements.",
"design_group_title": "UPA-ECx1 followed by ECx2",
"design_group_type": "Active Comparator",
"design_group_t... | [
"Obesity",
"Contraception"
] | [
"Oregon Health & Science University"
] | [
"National Institutes of Health"
] | [
[
{
"name": "醋酸乌利司他",
"lang": "CN"
},
{
"name": "Ulipristal Acetate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5e232aeae0e8a2e202de482225ee58a3",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "UPA-Obesity"
}
] |
NCT00000218 | [
{
"id_field": "org_study_id",
"id_value": [
"NIDA-06954-2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R18-06954-2"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R18-06954-2;NIDA-06954-2"
]
}
] | https://clinicaltrials.gov/study/NCT00000218 | Pharmacotherapy and Intensive Treatment - 2 | The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders. | Pharmacotherapy and Intensive Treatment | [
{
"name": "Carbamazepine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Cocaine-Related Disorders",
"Substance-Related Disorders"
] | [
"National Institute on Drug Abuse"
] | [
"VA Office of Research and Development"
] | [
[
{
"name": "卡马西平",
"lang": "CN"
},
{
"name": "Carbamazepine",
"lang": "EN"
},
{
"name": "カルバマゼピン",
"lang": "JP"
}
]
] | null |
NCT06799494 | [
{
"id_field": "org_study_id",
"id_value": [
"STUDY00008623"
]
}
] | https://clinicaltrials.gov/study/NCT06799494 | HPV Vaccine Reduced Dose | This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow.<br/>Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar... | Comparing the Antibody and B Cell Responses Induced by 1- or 2-dose 9-valent HPV (9vHPV) Vaccination in Healthy Adults | [
{
"description": "The 9-valent HPV VLP vaccine is a sterile liquid suspension prepared by combining the adsorbed VLPs of each HPV type and additional amounts of the aluminum-containing adjuvant and the final purification buffer. The 9-valent HPV vaccine, or Gardasil-9, is a sterile suspension for intramuscular ... | [
{
"design_group_description": "Participants will receive one dose of the 9-valent HPV (9vHPV) vaccine by intramuscular injection on Day 0.<br/>Participants will be asked to donate blood samples for immunologic testing at screening (from Day -60 to -1), on Day 0 (before vaccination), 7±1, 30±5, 180±5 (before vac... | [
"HPV"
] | [
"Emory University"
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "九价人乳头瘤病毒疫苗(酿酒酵母) (默沙东)",
"lang": "CN"
},
{
"name": "Human papillomavirus 9-valent vaccine, recombinant (Merck Sharp & Dohme)",
"lang": "EN"
},
{
"name": "組換え沈降9 価ヒトパピローマウイルス様粒子ワクチン（酵母由来）",
"lang": "JP"
}
],
[
{
"name": "利多卡因",
... | null |
NCT00452543 | [
{
"id_field": "org_study_id",
"id_value": [
"2006-P-001592/1"
]
}
] | https://clinicaltrials.gov/study/NCT00452543 | Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism | This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will improve outcomes for this population. | A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence | [
{
"description": "Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.",
"name": "acamprosate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Campral"
],
"type": "Drug"
},
{
"description": "Escitalopram is g... | [
{
"design_group_title": "Escitalopram plus acamprosate",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Based on the COMBINE study. 1 hour of medical management / behavioral in... | [
"Major Depressive Disorder",
"Alcohol Abuse",
"Alcohol Dependence"
] | [
"The General Hospital Corp."
] | [
"National Alliance for Research on Schizophrenia & Depression"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
],
[
{
"name": "阿坎酸钙",
"lang": "CN"
},
{
"name": "Acamprosate Calcium",
"lang": "EN"... | null |
NCT00505102 | [
{
"id_field": "org_study_id",
"id_value": [
"SAREFU123"
]
},
{
"id_field": "acronym",
"id_value": [
"SAREFU"
]
}
] | https://clinicaltrials.gov/study/NCT00505102 | Safe Renal Function In Long Term Heart Transplanted Patients | The purpose of this study is to verify whether the reduction of cyclosporine dosages associated with Everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy | Efficacy and Safety of Everolimus to SAve REnal Function (SAREFU) in Long Term Heart Transplanted Patients | [
{
"description": "cyclosporine dose reduced of 50% after introduction of everolimus",
"name": "Everolimus",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "A",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "cyclosporine dose reduced of 50% after introduction of everolimus",
"intervention_name"... | [
"Kidney Diseases",
"Heart Transplantation"
] | [
"A.O. Ospedale Papa Giovanni XXIII"
] | [
"Istituto di Ricerche Farmacologiche Mario Negri"
] | [
[
{
"name": "依维莫司",
"lang": "CN"
},
{
"name": "Everolimus",
"lang": "EN"
},
{
"name": "エベロリムス",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "SAREFU"
}
] |
NCT02852577 | [
{
"id_field": "org_study_id",
"id_value": [
"0003.0.249.000-09"
]
},
{
"id_field": "acronym",
"id_value": [
"LTTPANIC"
]
}
] | https://clinicaltrials.gov/study/NCT02852577 | Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine | The purpose of this study was to determine whether clonazepam and paroxetine are effective in the treatment of panic disorder. Efficacy was evaluated in short-term, long-term and post-treatment. | Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia | [
{
"description": "Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.",
"name": "Clonazepam",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_description": "Treatment with clonazepam",
"design_group_title": "Clonazepam",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Administration of clonaze... | [
"Panic Disorder",
"Agoraphobia"
] | [
"Federal University of Rio de Janeiro"
] | [
"Conselho Nacional de Desenvolvimento Cientifico e Tecnológico"
] | [
[
{
"name": "盐酸帕罗西汀",
"lang": "CN"
},
{
"name": "Paroxetine Hydrochloride",
"lang": "EN"
},
{
"name": "パロキセチン塩酸塩水和物",
"lang": "JP"
}
],
[
{
"name": "氯硝西泮",
"lang": "CN"
},
{
"name": "Clonazepam",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LTTPANIC"
}
] |
NCT05904743 | [
{
"id_field": "org_study_id",
"id_value": [
"MKC-TI-193"
]
}
] | https://clinicaltrials.gov/study/NCT05904743 | INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes | INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a pump without automation, and continuous glucose monitoring (CGM) 1:1 to an insulin regimen o... | INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes | [
{
"description": "Pharmaceutical form: powder Route of administration: inhalation",
"name": "Afrezza",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Technosphere Insulin"
],
"type": "Biological"
},
{
"description": "Pharmaceutical form: solution for in... | [
{
"design_group_description": "The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom Continuous Glucose Monitoring (CGM) will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin d... | [
"Diabetes Mellitus, Type 1"
] | [
"MannKind Corp."
] | [
"Jaeb Center For Health Research Foundation, Inc."
] | [
[
{
"name": "德谷胰岛素",
"lang": "CN"
},
{
"name": "Insulin degludec",
"lang": "EN"
},
{
"name": "インスリン デグルデク (遺伝子組換え)",
"lang": "JP"
}
],
[
{
"name": "人胰岛素",
"lang": "CN"
},
{
"name": "Insulin Recombinant Human(MannKind)",
... | [
{
"identifier_source": [
{
"code": "e44e8848a455aa38e22258553a5549ae",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "INHALE-3"
}
] |
NCT02476409 | [
{
"id_field": "org_study_id",
"id_value": [
"15-0472"
]
},
{
"id_field": "acronym",
"id_value": [
"TROUPER"
]
}
] | https://clinicaltrials.gov/study/NCT02476409 | Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders | Patients who present to clinic or in the outpatient setting with worsening heart failure represent a unique opportunity for novel approaches to decongestion (removing fluid) that may more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization.<br/>In these patients with less severe cong... | Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER) | [
{
"description": "Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.",
"name": "tolvaptan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Samsca"
],
"type": "D... | [
{
"design_group_description": "Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily",
"design_group_title": "Tolvaptan",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interve... | [
"Congestive Heart Failure"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"Otsuka America Pharmaceutical, Inc."
] | [
[
{
"name": "托伐普坦",
"lang": "CN"
},
{
"name": "Tolvaptan",
"lang": "EN"
},
{
"name": "トルバプタン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a892e99d82ede8e32e82e2202e28ee53",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "TROUPER"
}
] |
NCT07177417 | [
{
"id_field": "org_study_id",
"id_value": [
"202505085"
]
},
{
"id_field": "acronym",
"id_value": [
"EVax-3"
]
}
] | https://clinicaltrials.gov/study/NCT07177417 | Characterizing the Human Airway Immune Response to FluMist Vaccination | The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, volunteers between... | EVax-3: Human Upper and Lower Airway Mucosal Immune Response to FluMist Vaccination | [
{
"description": "intranasal administered live attenuated influenza vaccine",
"name": "FluMist",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "intramuscular administered inactivated influenza vaccine",
"name": "inactivated influenza vacc... | [
{
"design_group_description": "Individuals who undergo all bronchoscopy procedures randomized to receive FluMist vaccine",
"design_group_title": "FluMist bronchoscopy group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention... | [
"Healthy Young Adults",
"Influenza Vaccines",
"Influenza Vaccine Response"
] | [
"Washington University School of Medicine"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)",
"lang": "EN"
},
{
"name": "経鼻弱毒生インフルエンザワクチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EVax-3"
}
] |
NCT04790305 | [
{
"id_field": "org_study_id",
"id_value": [
"HE-202012"
]
}
] | https://clinicaltrials.gov/study/NCT04790305 | Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer | This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety o... | Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study | [
{
"description": "The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.",
"name": "Huaier Granule",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_description": "Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable.<br/>Conventional Treatment/visit：... | [
"Carcinoma Breast",
"Triple-negative Breast Cancer",
"Invasive Ductal Carcinoma, Breast"
] | [
"Fudan University"
] | [
"Huazhong University of Science & Technology",
"Linkdoc Technology (Beijing) Ltd."
] | [
[
{
"name": "槐耳颗粒",
"lang": "CN"
},
{
"name": "Huaier Granule",
"lang": "EN"
}
]
] | null |
NCT04661709 | [
{
"id_field": "org_study_id",
"id_value": [
"Wenxin granule-20201122"
]
}
] | https://clinicaltrials.gov/study/NCT04661709 | Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris | This is a double-blind, randomized placebo-controlled trial which aims to evaluate the efficacy and safety of Wen Xin granule in patients with unstable angina pectoris. | Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial | [
{
"description": "one dose daily, two times per day.",
"name": "Wen Xin granule",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"WXG"
],
"type": "Drug"
},
{
"description": "one tablet daily. (for patients who can't use aspirin)",
"name": "Clopidogre... | [
{
"design_group_description": "Patients are given Wen Xin granule by mouth, one dose daily for 2 months & Conventional western medicine, including Aspirin Enteric-coated Tablets 100mg qd, Clopidogrel Hydrogen Sulfate 75 mg qd, Atorvastatin Calcium 20mg qn, Isosorbide Mononitrate Tab 20 mg bid, Metoprolol Tartra... | [
"Coronary Heart Disease",
"Unstable Angina",
"Chinese Herbal Medicine"
] | [
"Guang'anmen Hospital, China Academy of Chinese Medical Sciences"
] | [
"National Natural Science Foundation of China"
] | [
[
{
"name": "阿托伐他汀钙",
"lang": "CN"
},
{
"name": "Atorvastatin Calcium",
"lang": "EN"
},
{
"name": "アトルバスタチンカルシウム水和物",
"lang": "JP"
}
],
[
{
"name": "酒石酸美托洛尔",
"lang": "CN"
},
{
"name": "Metoprolol Tartrate",
"lang": ... | null |
NCT05684731 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-TJ-KM1"
]
},
{
"id_field": "acronym",
"id_value": [
"K19017-004"
]
}
] | https://clinicaltrials.gov/study/NCT05684731 | Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer | The purpose of this study is to determine if KM1 is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer, and explore the Recommend Phase 2 Dose (RP2D) of KM1 in the treatment of patients with recurrent or refractory ovarian cancer. | A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of KM1 Oncolytic Vaccinia Virus Injection Combined With Chemotherapy in Subjects With Recurrent or Refractory Ovarian Cancer | [
{
"description": "Administer via intraperitoneal infusion for 3 or 6 doses Q3D.",
"name": "KM1",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, doceta... | [
{
"design_group_description": "Biological: KM1 Administer via intraperitoneal infusion for 3 or 6 doses Q3D.<br/>Drug: Chemotherapy: Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevaciz... | [
"Ovarian Cancer"
] | [
null
] | [
"Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd.",
"Qilu Hospital of Shandong University"
] | [
[
{
"name": "KM1溶瘤痘苗病毒(Shenzhen Huayao Kangming Biopharmaceutical)",
"lang": "CN"
},
{
"name": "Oncolytic vaccinia virus (Huayao Kangming)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "K19017-004"
}
] |
NCT02792114 | [
{
"id_field": "org_study_id",
"id_value": [
"16-040"
]
}
] | https://clinicaltrials.gov/study/NCT02792114 | T-Cell Therapy for Advanced Breast Cancer | The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer. | A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer | [
{
"name": "Cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "Mesothelin-targeted T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "AP1903",
"normalized_type": "3d1aa88261d64... | [
{
"design_group_description": "A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via in... | [
"Breast Cancer",
"Metastatic HER2-negative Breast"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Defense Language Institute Foreign Language Center"
] | [
[
{
"name": "ATA-2271",
"lang": "EN"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "Rimiducid",
"lang": "EN"
}
... | null |
NCT04015700 | [
{
"id_field": "org_study_id",
"id_value": [
"202003072"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01NS112712"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R01NS112712;202003072"
]
}
] | https://clinicaltrials.gov/study/NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | This is a single institution, open-label, single arm, study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine in subjects with newly diagnosed, unmethylated glioblastoma. | A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma | [
{
"description": "-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.",
"name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"GNOS-PV01",
"Va... | [
{
"design_group_description": "* Standard radiation therapy will be administered per standard of care and is outside the scope of this study.<br/>* GNOS-PV01 + INO-9012 will be given on Days 1, 22, and 43 of Cycle 1 and then on Day 1 of each subsequent cycle beginning with Cycle 2.",
"design_group_title": "... | [
"Glioblastoma"
] | [
"Washington University School of Medicine"
] | [
"National Institute of Neurological Disorders & Stroke",
"Geneos Therapeutics, Inc.",
"Barnes-Jewish Hospital Foundation"
] | [
[
{
"name": "Rocakinogene Sifuplasmid",
"lang": "EN"
}
],
[
{
"name": "GNOS PV01 + INO 9012",
"lang": "EN"
}
]
] | null |
NCT02063555 | [
{
"id_field": "org_study_id",
"id_value": [
"DAR-901-MDES"
]
}
] | https://clinicaltrials.gov/study/NCT02063555 | Phase I Trial of DAR-901 | This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are to determine the safety, tolerability, and immunogen... | A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG | [
{
"name": "DAR-901",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "BCG",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "Sterile saline",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af... | [
{
"design_group_description": "Intradermal administration at 0, 2 and 4 months<br/>Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL",
"design_group_title": "DAR-901",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480... | [
"Tuberculosis"
] | [
"Dartmouth-Hitchcock Medical Center"
] | [
"Aeras Global TB Vaccine Foundation"
] | [
[
{
"name": "IMM-201",
"lang": "EN"
}
]
] | null |
NCT06249438 | [
{
"id_field": "org_study_id",
"id_value": [
"1141-043(CAR-AID)"
]
},
{
"id_field": "acronym",
"id_value": [
"CAR-AID"
]
}
] | https://clinicaltrials.gov/study/NCT06249438 | A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy | An Exploratory Clinical Study of Cluster of Differentiation Antigen 20(CD20)/Anti-B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy | [
{
"description": "Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously",
"name": "CD20/BCMA-directed CAR-T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"C-CAR168"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Autologous C-CAR168 administered by intravenous (IV) infusion",
"design_group_title": "C-CAR168",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description... | [
"Systemic Lupus Erythematosus (SLE)",
"Immune-mediated Necrotizing Myopathy (IMNM)",
"Neuromyelitis Optica Spectrum Disorders (NMOSD)",
"Multiple Sclerosis (MS)",
"Myasthenia Gravis",
"Systemic Sclerosis (SSc)"
] | [
"Shanghai Renji Hospital"
] | [
"AbelZeta Pharma, Inc."
] | [
[
{
"name": "C-CAR168",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CAR-AID"
}
] |
NCT03233932 | [
{
"id_field": "org_study_id",
"id_value": [
"155HPS14022"
]
}
] | https://clinicaltrials.gov/study/NCT03233932 | CKD-841 Pharmacokinetic/Pharmacodynamic Study | A randomized, open-label, single dose, parallel design phase I clinical trial to investigate the safety and pharmacokinetic/pharmacodynamics of CKD-841 or Leuplin Inj. 3.75mg after subcutaneous injection in postmenopausal female. | Clinical Trial to Investigate the Safety and Pharmacokinetics/Pharmacodynamics of CKD-841 After Subcutaneous Injection in Postmenopausal Female | [
{
"description": "Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.",
"name": "LeuplinⓡInj",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Investigational drug(=CDK-841) is pres... | [
{
"design_group_description": "LeuplinⓡInj(=leuprorelin acetate 3.75mg)",
"design_group_title": "LeuplinⓡInj",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Investiga... | [
"Postmenopausal Disorder"
] | [
"Chong Kun Dang Pharmaceutical Corp."
] | [
"Severance Hospital"
] | [
[
{
"name": "亮丙瑞林",
"lang": "CN"
},
{
"name": "Leuprorelin",
"lang": "EN"
}
]
] | null |
NCT01825603 | [
{
"id_field": "org_study_id",
"id_value": [
"0470-12-FB"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2013-00406"
]
},
{
"id_field": "secondary_id",
"id_type... | https://clinicaltrials.gov/study/NCT01825603 | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer | This phase I trial studies the side effects and best dose of ADH-1 when given together with gemcitabine hydrochloride and cisplatin in treating patients with pancreatic or biliary tract cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or spread to other parts of the body (... | A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers | [
{
"description": "Given IV",
"name": "ADH-1",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Exherin"
],
"type": "Drug"
},
{
"description": "Given IV",
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name":... | [
{
"design_group_description": "Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with ... | [
"Ampulla of Vater Adenocarcinoma",
"Gallbladder Adenocarcinoma",
"Metastatic Pancreatic Adenocarcinoma",
"Pancreatic Adenocarcinoma",
"Stage III Ampulla of Vater Cancer",
"Stage III Intrahepatic Cholangiocarcinoma",
"Stage III Pancreatic Cancer",
"Stage IIIA Gallbladder Cancer",
"Stage IIIA Hilar Ch... | [
"University of Nebraska"
] | [
"National Cancer Institute",
"Fennec Pharmaceuticals, Inc."
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{... | null |
NCT01670136 | [
{
"id_field": "org_study_id",
"id_value": [
"11-1646"
]
},
{
"id_domain": "NICHD",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"HHSN27500014"
]
}
] | https://clinicaltrials.gov/study/NCT01670136 | Pharmacokinetics of Sildenafil in Premature Infants | The purpose of this study is to learn more about the safety and dosing of sildenafil in infants. | Pharmacokinetics of Sildenafil in Premature Infants | [
{
"description": "A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.",
"name": "1 dose of ... | [
{
"design_group_description": "Infants receiving sildenafil as standard of care",
"design_group_title": "sildenafil, standard of care",
"design_group_type": "No Intervention"
},
{
"design_group_description": "1 dose of sildenafil administered for study",
"design_group_title": "sildenafil adm... | [
"Persistent Pulmonary Hypertension of the Newborn"
] | [
"The University of North Carolina at Chapel Hill"
] | [
"The Emmes Co. LLC",
"Duke University",
"National Institute of Child Health & Human Development"
] | [
[
{
"name": "枸橼酸西地那非",
"lang": "CN"
},
{
"name": "Sildenaifl Citrate",
"lang": "EN"
},
{
"name": "シルデナフィルクエン酸塩",
"lang": "JP"
}
]
] | null |
NCT00115726 | [
{
"id_field": "org_study_id",
"id_value": [
"15326"
]
},
{
"id_field": "secondary_id",
"id_value": [
"15326"
]
}
] | https://clinicaltrials.gov/study/NCT00115726 | Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure | The purpose of this study is to determine whether continuing or discontinuing furosemide (a diuretic) on the day of elective noncardiac surgery for those who take furosemide on a chronic basis, causes more intraoperative hypotension (low blood pressure) during surgery. Our hypothesis is that the usual practice of conti... | Randomized Controlled Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure | [
{
"description": "for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)",
"name": "furosemide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description"... | [
{
"design_group_description": "furosemide",
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "for patients on chronic furosemide therapy, patients a... | [
"Hypertension",
"Hypotension",
"Edema",
"Congestive Heart Failure"
] | [
"University of Calgary"
] | [
"The Center for the Advancement of Health IT"
] | [
[
{
"name": "呋塞米",
"lang": "CN"
},
{
"name": "Furosemide",
"lang": "EN"
},
{
"name": "フロセミド",
"lang": "JP"
}
]
] | null |
NCT00108368 | [
{
"id_field": "org_study_id",
"id_value": [
"MHBS-057-00S"
]
}
] | https://clinicaltrials.gov/study/NCT00108368 | The Effects of Risperidone and Olanzapine on Thinking | The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition.<br/>Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception. | The Cognitive Effects of Risperidone and Olanzapine | [
{
"name": "Risperidone",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "Olanzapine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Schizophrenia",
"Psychotic Disorders"
] | [
"US Department of Veterans Affairs (District of Columbia)"
] | [
"Janssen LP"
] | [
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"name": "リスペリドン",
"lang": "JP"
}
],
[
{
"name": "奥氮平",
"lang": "CN"
},
{
"name": "Olanzapine",
"lang": "EN"
},
{
"name": "オラ... | null |
NCT04066088 | [
{
"id_field": "org_study_id",
"id_value": [
"19-00936"
]
}
] | https://clinicaltrials.gov/study/NCT04066088 | Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome | This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects. | Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome | [
{
"description": "Placebo will be administered same times as GXR",
"name": "Placebo",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"description": "The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be rais... | [
{
"design_group_title": "Placebo",
"design_group_type": "Sham Comparator",
"design_group_type_normalized_id": "04ffa020e2dd36309e7dfddadf448893",
"intervention": [
{
"intervention_description": "Placebo will be administered same times as GXR",
"intervention_name": "Placebo",
... | [
"Prader-Willi Syndrome"
] | [
"NYU Langone Health"
] | [
"Winthrop-University Hospital, Inc."
] | [
[
{
"name": "盐酸胍法辛",
"lang": "CN"
},
{
"name": "Guanfacine hydrochloride",
"lang": "EN"
},
{
"name": "グアンファシン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00538512 | [
{
"id_field": "org_study_id",
"id_value": [
"FLUVACS"
]
},
{
"id_field": "acronym",
"id_value": [
"FLUVACS"
]
}
] | https://clinicaltrials.gov/study/NCT00538512 | Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4 | The purpose of this study is to evaluate the absolute (versus placebo) and relative (one vaccine compared to the other) efficacies of the live attenuated and inactivated influenza vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating strains whether similar or dissimilar to strains inc... | Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4 | [
{
"description": "single dose licensed trivalent inactivated influenza vaccine (2007-08)",
"name": "Fluzone",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "single dose licensed live-attenuated influenza vaccine Flumist (2007-08)",
"name"... | [
{
"design_group_description": "the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur",
"design_group_title": "TIV",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"... | [
"Influenza"
] | [
"University of Michigan"
] | [
"Sanofi Pasteur SA"
] | [
[
{
"name": "四价流感病毒裂解疫苗(Sanofi)",
"lang": "CN"
},
{
"name": "Tetravalent influenza vaccine(Split, inactivated)(Sanofi)",
"lang": "EN"
}
],
[
{
"name": "Influenza virus vaccine live intranasal (quadrivalent)(MedImmune LLC)",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5882550e22d494e8a82e2555d2e248e9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "5ad38ae3e823a8a203a283aa54225ea5",
"s... |
NCT01015638 | [
{
"id_field": "org_study_id",
"id_value": [
"114546"
]
}
] | https://clinicaltrials.gov/study/NCT01015638 | Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications | This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide 5% or clindamycin phosphate and benzoyl peroxide 2.5% and the other side of the face will remain no... | Two-week Study to Determine and Compare the Tolerance and Irritation Potential of Duac® Topical Gel (Clindamycin 1% and Benzoyl Peroxide 5%) to ACANYA™ Gel (Clindamycin Phosphate 1.2% and Benzoyl Peroxide 2.5%) Topical Acne Medications | [
{
"description": "Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.",
"name": "Clindamycin and BPO 5% gel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Duac Topical Gel"
],
"ty... | [
{
"design_group_description": "Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.",
"design_group_title": "Clindamycin and BPO 5% gel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b556156... | [
"Acne Vulgaris"
] | [
"Stiefel Laboratories, Inc."
] | [
"GSK Plc"
] | [
[
{
"name": "克林霉素磷酸酯/过氧苯甲酰",
"lang": "CN"
},
{
"name": "Benzoyl Peroxide/Clindamycin Phosphate",
"lang": "EN"
},
{
"name": "クリンダマイシンリン酸エステル水和物/過酸化ベンゾイル",
"lang": "JP"
}
]
] | null |
NCT00167557 | [
{
"id_field": "org_study_id",
"id_value": [
"HSC-MS-04-0346"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Astellas Pharma"
]
},
{
"id_field": "secondary_id",
"id_value": [
"FHIprojectno.JK-04-002"
]
}
] | https://clinicaltrials.gov/study/NCT00167557 | Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment | After a liver transplant, the hepatitis C virus (which destroyed one's own liver) eventually comes back. In many patients, this will eventually cause the loss of the new liver and can also confuse the doctors taking care of them because it is hard to tell the difference between one's body rejecting the new liver and he... | Tacrolimus Monotherapy in OLT Recipients With HCV Under Preemptive Treatment With Interferon and Ribavirin | [
{
"description": "180mcg SC weekly starting 30 days post transplant",
"name": "Pegylated Interferon",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks",
"name": "Ribaviri... | [
{
"design_group_title": "Single Arm Study",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "180mcg SC weekly starting 30 days post transplant",
"intervention_name": "Peg... | [
"Hepatitis C"
] | [
"The University of Texas Health Science Center at Houston"
] | [
"Astellas Pharma US, Inc."
] | [
[
{
"name": "利巴韦林",
"lang": "CN"
},
{
"name": "Ribavirin",
"lang": "EN"
},
{
"name": "リバビリン",
"lang": "JP"
}
]
] | null |
NCT02281305 | [
{
"id_field": "org_study_id",
"id_value": [
"22977 / 29-08-2014"
]
}
] | https://clinicaltrials.gov/study/NCT02281305 | Post-MI PET Scan Imaging of Inflammation | Restoring the patency of the coronary vessels and providing the ischemic myocardium with reperfused blood can cause additional tissue damage. A key element of ischemia and reperfusion (I/R) injury and major determinant of the evolution of damage in the affected myocardium is the inflammatory response. The main objectiv... | Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine | [
{
"name": "Colchicine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days",
"design_group_title": "Colchicine Active treatment group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"int... | [
"Acute Myocardial Infarction"
] | [
"General Hospital G. Gennimatas"
] | [
"Academy of Athens"
] | [
[
{
"name": "秋水仙碱",
"lang": "CN"
},
{
"name": "Colchicine",
"lang": "EN"
},
{
"name": "コルヒチン",
"lang": "JP"
}
]
] | null |
NCT00555087 | [
{
"id_field": "org_study_id",
"id_value": [
"2006/1084"
]
},
{
"id_field": "acronym",
"id_value": [
"Nebidolocal"
]
}
] | https://clinicaltrials.gov/study/NCT00555087 | Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate | The main objective of this study is to evaluate the response of erectile dysfunction in hypogonadotrophic males with Testosterone undecanoate i.m. as per IIEF and the question of the GAQ (Global Evaluation Questionnaire) after 42 weeks of treatment.<br/>Secondary Study Objectives<br/>* To monitor adverse events and cha... | Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate i.m. 1000 mg. A Prospective, Multi-Center Clinical Study Phase IV. | [
{
"description": "Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg",
"name": "Testosterone Undecanoate and/or PDE-5",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Levitra",
"Nebido"
],
"type": "Drug"
}
] | [
{
"design_group_description": "It is and intervention study with 1 arm",
"design_group_title": "A= Nebido",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Testosterone Unde... | [
"Erectile Dysfunction",
"Hypogonadotrophic Males"
] | [
"Hospital Santa Fe SA de CV"
] | [
"Bayer AG"
] | [
[
{
"name": "十一酸睾酮",
"lang": "CN"
},
{
"name": "Testosterone Undecanoate",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Nebidolocal"
}
] |
NCT05757167 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00110771"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"1U01AI162463-01A1"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
... | https://clinicaltrials.gov/study/NCT05757167 | Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics | The purpose of the INTREPiD study is to compare 1st trimester screening for malaria parasites with a high-sensitivity malaria rapid diagnostic test followed by treatment of test-positive women with artemether-lumefantrine (AL) against usual antenatal care on a composite adverse pregnancy outcome including low birth wei... | Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity | [
{
"description": "Detection of Plasmodium falciparum HRP-II antigen1<br/>Method: Lateral Flow; Time to Result: 20 minutes; Sample Type: Fingerstick Whole Blood; Sample Volume: 5µl; Storage Conditions: 1-30°C; Shelf Life: 12 months; Sensitivity/Specificity: 99.0%/98.6%",
"name": "Malaria High-Sensitivity Rap... | [
{
"design_group_description": "Pregnant women will be screened with a malaria HS-RDT and, if positive, treated with artemether-lumefantrine",
"design_group_title": "HS-RDT screening/AL treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5... | [
"Malaria,Falciparum",
"Malaria in Pregnancy",
"Malaria in Childbirth",
"Pregnancy",
"Neonatal Health",
"Low Birthweight",
"Stillbirth",
"Gestational Age and Weight Conditions",
"Preterm Birth"
] | [
"Duke University"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
[
{
"name": "复方蒿甲醚",
"lang": "CN"
},
{
"name": "Artemether/Lumefantrine",
"lang": "EN"
},
{
"name": "アルテメテル/ルメファントリン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "INTREPiD"
}
] |
NCT05900427 | [
{
"id_field": "org_study_id",
"id_value": [
"EH23-069"
]
}
] | https://clinicaltrials.gov/study/NCT05900427 | Effects on Postoperative Pain of Liposomal Bupivacaine in Interscalene Blocks for Total Shoulder Arthroplasty Patients | The purpose of this trial is to compare the difference in the proportion of patients with tolerable pain scores, VAS pain scores, quality of recovery and opioid use in milligram equivalents (at 24, 48, 72, 96 and 120 hours postoperatively) in patients undergoing shoulder arthroplasty who receive interscalene blocks wit... | A Double-Blind Randomized Comparison Trial of Postoperative Pain in Patients Undergoing Total Shoulder Arthroplasty Who Receive Interscalene Blocks With or Without Liposomal Bupivacaine (PoPTSAWoW Trial) | [
{
"description": "Subjects randomized to the Liposomal bupivacaine group will receive 10 mL (133 mg) of Liposomal bupivacaine and 20 mL (50 mg) of 0.25% bupivacaine and 6 mL of saline (183 mg).",
"name": "Liposomal bupivacaine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
... | [
{
"design_group_description": "10 mL (133 mg) Liposomal bupivacaine and 20 mL (50 mg) 0.25% bupivacaine and 6 mL of saline (183 mg)",
"design_group_title": "Liposomal Bupivacaine Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"... | [
"Total Shoulder Arthroplasty",
"Reverse Total Shoulder Arthroplasty"
] | [
"Endeavor Health"
] | [
"Endeavor Health"
] | [
[
{
"name": "布比卡因脂质体",
"lang": "CN"
},
{
"name": "Bupivacaine liposome",
"lang": "EN"
}
]
] | null |
NCT03973489 | [
{
"id_field": "org_study_id",
"id_value": [
"17932"
]
},
{
"id_field": "acronym",
"id_value": [
"MATAAR"
]
}
] | https://clinicaltrials.gov/study/NCT03973489 | Effects of Genotype on Resting State Connectivity During Methamphetamine Administration | Addiction to methamphetamine (MA) is a serious health problem in the United States. Right now, there are no medically approved treatments for MA dependence. More research is needed to understand how MA affects the brain and to eventually develop medical interventions for MA addiction. The purpose of the study is to lea... | Effects of Genotype on Resting State Connectivity During Methamphetamine Administration | [
{
"description": "On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.",
"name": "Magnetic resonance imaging (MRI)",
"normalized_type": "f9cf04e7d3da41f2ae5e... | [
{
"design_group_description": "Wild Type (WT) Group: individuals who are WT for the TAAR1 gene",
"design_group_title": "Wild Type (WT) MUD Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"interv... | [
"Methamphetamine-dependence"
] | [
"Oregon Health & Science University"
] | [
"Portland VA Medical Center"
] | [
[
{
"name": "盐酸去氧麻黄碱",
"lang": "CN"
},
{
"name": "Methamphetamine Hydrochloride",
"lang": "EN"
},
{
"name": "メタンフェタミン塩酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MATAAR"
}
] |
NCT03797014 | [
{
"id_field": "org_study_id",
"id_value": [
"HP00083844"
]
},
{
"id_field": "acronym",
"id_value": [
"BEST-HBV"
]
}
] | https://clinicaltrials.gov/study/NCT03797014 | B/F/TAF Switch Study for HIV-HBV Coinfection | The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B. As this is a switch study, all eligible subjects enrolled will be switched from their current antiret... | Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-HBV Coinfection | [
{
"description": "Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.",
"name": "B/F/TAF",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Bictegravir/emtricitabine/tenofovir alafenamide"
],
"type... | [
{
"design_group_description": "Treatment group (1-arm study)",
"design_group_title": "B/F/TAF",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Fixed dose combination B/F/TA... | [
"HIV-1-infection",
"Hepatitis B"
] | [
"University of Maryland Baltimore"
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "富马酸丙酚替诺福韦/恩曲他滨/比克替拉韦",
"lang": "CN"
},
{
"name": "Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate",
"lang": "EN"
},
{
"name": "ビクテグラビルナトリウム/エムトリシタビン/テノホビル アラフェナミドフマル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "883582da024a45a8da8ad23e288a20e2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BEST-HBV"
}
] |
NCT06563102 | [
{
"id_field": "org_study_id",
"id_value": [
"D6930C00018"
]
},
{
"id_field": "acronym",
"id_value": [
"DARWIN"
]
},
{
"id_field": "secondary_id",
"id_value": [
"D6930C00018"
]
}
] | https://clinicaltrials.gov/study/NCT06563102 | Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma | The purpose of this study is to compare the efficacy and safety of albuterol/budesonide to albuterol in changes in airway inflammation, asthma symptoms, and rescue therapy utilization in adults with mild asthma.<br/>Study details include:<br/>* The study duration will be up to 15 weeks.<br/>* The treatment duration wil... | A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered as Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults With Mild Asthma | [
{
"description": "Oral Inhalation. Rescue medication. Unit dose strength of 80 μg budesonide and 90 μg albuterol per actuation",
"name": "Albuterol/Budesonide",
"normalized_type": "26823d77f12d4744a960c336f01c2d6e",
"other_name": [
"AIRSUPRA",
"BDA MDI HFA"
],
"type": "Combinatio... | [
{
"design_group_description": "Participants will be randomized based on Visit 1 FeNO levels (< 50 ppb / ≥ 50 ppb) and geographic region. Participants who are randomized to receive albuterol/budesonide for as-needed rescue therapy will be compared to participants randomized to receive albuterol for as-needed res... | [
"Mild Asthma"
] | [
"AstraZeneca PLC"
] | [
"Fortrea, Inc."
] | [
[
{
"name": "沙丁胺醇/布地奈德",
"lang": "CN"
},
{
"name": "Albuterol/Budesonide",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DARWIN"
}
] |
NCT00314327 | [
{
"id_field": "org_study_id",
"id_value": [
"05.04.161"
]
},
{
"id_field": "acronym",
"id_value": [
"ORP"
]
}
] | https://clinicaltrials.gov/study/NCT00314327 | Optimizing Response in Psychosis Study | The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial. | Optimizing Response in Psychosis Study | [
{
"description": "One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. Th... | [
{
"design_group_description": "One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of... | [
"Schizophrenia",
"Schizoaffective Disorder",
"Schizophreniform Disorder",
"Psychotic Disorder Not Otherwise Specified"
] | [
"Northwell Health, Inc."
] | [
"National Alliance for Research on Schizophrenia & Depression"
] | [
[
{
"name": "利培酮",
"lang": "CN"
},
{
"name": "Risperidone",
"lang": "EN"
},
{
"name": "リスペリドン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "922a92da23e225020ed8a5852884e0d2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ORP"
}
] |
NCT01839110 | [
{
"id_field": "org_study_id",
"id_value": [
"817785"
]
}
] | https://clinicaltrials.gov/study/NCT01839110 | Targeting the Right Ventricle in Pulmonary Hypertension | This study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension specific therapies but with right ventricular dysfunction (RVEF <45%) would improve their outcome. This study is accompanied by a baseline comparison of the metabolic profiling/microRNA/iPS cells of subjects with and without ... | A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular... | [
{
"description": "Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.",
"name": "Ranolazine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ranexa"
],
"type": "Drug... | [
{
"design_group_description": "Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day",
"design_group_title": "Ranolazine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"int... | [
"Pulmonary Hypertension"
] | [
"University of Pennsylvania"
] | [
"University of Maryland",
"Washington University School of Medicine",
"Yale University",
"The Brigham & Women's Hospital, Inc."
] | [
[
{
"name": "雷诺嗪",
"lang": "CN"
},
{
"name": "Ranolazine",
"lang": "EN"
}
]
] | null |
NCT01488526 | [
{
"id_field": "org_study_id",
"id_value": [
"IN-US 174-0174"
]
}
] | https://clinicaltrials.gov/study/NCT01488526 | Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus | Immunoprophylaxis failure of hepatitis B virus (HBV) leading to vertical transmission remains a concern and has been reported in approximately 8-15% of infants born to hepatitis B e antigen (HBeAg) positive mothers with high levels of HBV DNA. Maternal HBV DNA > 6log10 copies/mL (or >200,000 IU/mL) is the major risk fo... | Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers | [
{
"description": "About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.",
"name": "TDF treatment",
"normalized_type": "3d1aa88261d64c038413723970f... | [
{
"design_group_description": "Provide standard of care to mothers and standard immunoprophylaxis to their infants",
"design_group_title": "Control arm: HBIG & vaccine for infants",
"design_group_type": "No Intervention"
},
{
"design_group_description": "tenofovir from 30-32 weeks of pregnancy t... | [
"Hepatitis B Infection",
"Chronic Infection",
"Viremia"
] | [
"New Discovery, Inc."
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "富马酸替诺福韦二吡呋酯",
"lang": "CN"
},
{
"name": "Tenofovir Disoproxil Fumarate",
"lang": "EN"
},
{
"name": "テノホビル ジソプロキシルフマル酸塩",
"lang": "JP"
}
]
] | null |
NCT04587843 | [
{
"id_field": "org_study_id",
"id_value": [
"COR Weight Regain Study"
]
},
{
"id_field": "acronym",
"id_value": [
"COR-WR"
]
}
] | https://clinicaltrials.gov/study/NCT04587843 | A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery | Contrave (naltrexone HCl and bupropion HCl) extended-release tablet is an approved drug and indicated to be used with a low calorie diet and increased physical activity for chronic weight management in obese adults (BMI 30 Kg/m2 or greater) or overweight adults (BMI 27 Kg/m2 or greater) with at least one weight related... | A Randomized Controlled Trial Evaluating the Effectiveness of Contrave (Naltrexone HCl and Bupropion HCl) in Patients Who Have Weight Recidivism Following Bariatric Surgery: Contrave Obesity Trials (COR) Weight Regain Study | [
{
"description": "Each Contrave Extended Release Tablet contains 8Mg of naltrexone HCl and 90Mg of bupropion HCl and will be administered orally. Total daily dose is 32Mg / 360Mg.<br/>Participants randomized to the treatment arm will be administered 4 Contrave tablets a day for 1 year (2 tablets taken twice a d... | [
{
"design_group_description": "Group treated with Contrave Extended Release Tablets",
"design_group_title": "Contrave 8mg/90mg Extended Release Tablet",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"... | [
"Obesity"
] | [
"St. Joseph's Healthcare Hamilton"
] | [
"Bausch Health, Canada, Inc."
] | [
[
{
"name": "盐酸纳曲酮/盐酸安非他酮",
"lang": "CN"
},
{
"name": "Bupropion Hydrochloride/Naltrexone Hydrochloride",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COR-WR"
}
] |
NCT00896389 | [
{
"id_field": "org_study_id",
"id_value": [
"HP-00040712"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R21DK084566"
]
},
{
"id_field": "acronym",
"id_value": [
"SALTI"
]
}
] | https://clinicaltrials.gov/study/NCT00896389 | Salt Loading and Thiazide Intervention Study | The investigators of this study propose to examine the relationships between STK39 (Serine Threonine Kinase 39) genotypes and responses to salt loading and to thiazide diuretics, hydrochlorothiazide. The investigators hypothesize that STK39 genotypes will be associated with the outcome of both interventions and can con... | The Relationship Between Serine Threonine Kinase 39 (STK39) Genotypes, Salt Sensitivity, Thiazide Diuretics-induced Blood Pressure Response | [
{
"description": "Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will... | [
{
"design_group_description": "Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week",
"design_group_title": "Salt-loading and thiazide diuretic (HCTZ)",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "Subjects will arrive at the Amish Resear... | [
"Hypertension"
] | [
"University of Maryland Baltimore"
] | [
"National Institute of Diabetes & Digestive & Kidney Diseases"
] | [
[
{
"name": "氢氯噻嗪",
"lang": "CN"
},
{
"name": "Hydrochlorothiazide",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "353a29ae4083e288252a3dea8e2ae2a8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "SALTI"
}
] |
NCT00371501 | [
{
"id_field": "org_study_id",
"id_value": [
"HARECCTR0500059"
]
}
] | https://clinicaltrials.gov/study/NCT00371501 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus | The purpose of this trial is to study if aspirin and statins (lipid-lowering agents) can reduce the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE). | Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial | [
{
"description": "10mg/day",
"name": "Rosuvastatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Crestor"
],
"type": "Drug"
},
{
"description": "one tablet/day",
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"t... | [
{
"design_group_title": "treatment arm 1",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "10mg/day",
"intervention_name": "Rosuvastatin",
"intervention_oth... | [
"Atherosclerosis",
"Thromboembolism",
"Systemic Lupus Erythematosus"
] | [
"Tuen Mun Hospital"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "瑞舒伐他汀钙",
"lang": "CN"
},
{
"name": "Rosuvastatin Calcium",
"lang": "EN"
},
{
"name": "ロスバスタチンカルシウム",
"lang": "JP"
}
],
[
{
"name": "阿司匹林",
"lang": "CN"
},
{
"name": "Aspirin",
"lang": "EN"
},
{
... | null |
NCT01870635 | [
{
"id_field": "org_study_id",
"id_value": [
"RSO1026252"
]
},
{
"id_field": "acronym",
"id_value": [
"OWEP"
]
}
] | https://clinicaltrials.gov/study/NCT01870635 | Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan | The primary objective is to determine if the administration of a single dose of oral ondansetron (an anti-vomiting medication), compared to placebo, results in a reduction in intravenous (IV) rehydration therapy in children presenting for emergency department care with vomiting and diarrhea in Pakistan. | Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in Emergency Departments in Pakistan | [
{
"description": "Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.",
"name": "Ondansetron",
"normalized_ty... | [
{
"design_group_description": "4 mg oral disintegrating tablet of ondansetron<br/>Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)",
"design_group_title": "Ondansetron",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5... | [
"Dehydration",
"Gastroenteritis",
"Vomiting",
"Diarrhea"
] | [
"University of Calgary"
] | [
"Gates Foundation (United States)",
"Aga Khan University",
"Thrasher Research Fund"
] | [
[
{
"name": "盐酸昂丹司琼",
"lang": "CN"
},
{
"name": "Ondansetron Hydrochloride",
"lang": "EN"
},
{
"name": "オンダンセトロン塩酸塩水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "OWEP"
}
] |
NCT03149887 | [
{
"id_field": "org_study_id",
"id_value": [
"PRO17020089"
]
}
] | https://clinicaltrials.gov/study/NCT03149887 | Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair | Liposomal bupivacaine, a long-acting form of bupivacaine, has been found to be effective for postoperative pain control after total knee, total hip and total shoulder arthroplasty. We are conducting a randomized, controlled trial to evaluate pain control after arthroscopic rotator cuff repair in ambulatory patients, co... | Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair | [
{
"description": "Liposomal bupivacaine solution (Exparel) for injection",
"name": "Liposomal bupivacaine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Exparel"
],
"type": "Drug"
},
{
"description": "Inert solution created to appear as liposomal bupi... | [
{
"design_group_description": "Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.",
"design_group_title": "Experimental",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Rotator Cuff Tear"
] | [
"University of Pittsburgh"
] | [
"Pacira Biosciences, Inc."
] | [
[
{
"name": "布比卡因脂质体",
"lang": "CN"
},
{
"name": "Bupivacaine liposome",
"lang": "EN"
}
]
] | null |
NCT04448028 | [
{
"id_field": "org_study_id",
"id_value": [
"STOPPIT-01"
]
},
{
"id_domain": "German Federal Ministry of Education and Research",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"01KG2004"
]
},
{
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT04448028 | Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial | Proton-pump inhibitors (PPI) are commonly prescribed in an uncritical manner to patients with liver cirrhosis without a clear evidence-based indication. Observational studies suggests that PPI use in cirrhotic patients may be a risk factor for the development of infections, especially spontaneous bacterial peritonitis ... | Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial | [
{
"description": "Patients with a pre-existing PPI therapy discontinue PPI therapy and replace it with placebo over a period of 346 days after a 14 day dose tapering phase.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Patient... | [
{
"design_group_description": "Patients randomized to the intervention group discontinue their pre-existing PPI treatment and replace it with placebo (day 15 to 360). During the first 14 days (dose tapering phase) patients in the intervention group will receive placebo on day 1, 3, 5, 7, 9, 10, 12, 13 and esome... | [
"Liver Cirrhosis"
] | [
"Universitätsklinikum Hamburg-Eppendorf"
] | [
"University Hospital Heidelberg",
"German Federal Ministry Of Education And Research"
] | [
[
{
"name": "埃索美拉唑镁",
"lang": "CN"
},
{
"name": "Esomeprazole Magnesium",
"lang": "EN"
},
{
"name": "エソメプラゾールマグネシウム水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "STOPPIT"
}
] |
NCT05563155 | [
{
"id_field": "org_study_id",
"id_value": [
"Repeat Dose"
]
}
] | https://clinicaltrials.gov/study/NCT05563155 | Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response | The aim of the study is to compare the effect of a repeat moderate dose of glucocorticoids postoperatively after preoperative high dose upon postoperative pain after Total Knee Arthroplasty (TKA) in an High Pain Respondes (HPR) population to a standard single high dose systemic preoperative administration in an HPR pop... | Repeat Dose Steroid to Prevent Pain Relapse After Total Knee Arthroplasty in Patients With High Pain Response - A Randomized Double-blind Placebo-controlled Trial | [
{
"description": "Dexamethasone 24 mg on day 1 after surgery.",
"name": "Dexamethasone 24 mg",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Dexa-ratiopharm"
],
"type": "Drug"
},
{
"description": "Placebo tablet given on day 1 after surgery.",
"nam... | [
{
"design_group_description": "Control Group (CG):<br/>Intervention: Postoperative oral placebo tablet on day 1 after surgery given as one single dose.",
"design_group_title": "Placebo tablet on day 1 after surgery given as one single dose.",
"design_group_type": "Placebo Comparator",
"design_group_... | [
"Post Operative Pain, Acute"
] | [
"Vejle Hospital"
] | [
"Hvidovre University Hospital"
] | [
[
{
"name": "地塞米松磷酸钠",
"lang": "CN"
},
{
"name": "Dexamethasone Sodium Phosphate",
"lang": "EN"
},
{
"name": "デキサメタゾンリン酸エステルナトリウム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Repeat Dose"
}
] |
NCT02777580 | [
{
"id_field": "org_study_id",
"id_value": [
"LRD.2016.STREAM2"
]
},
{
"id_field": "acronym",
"id_value": [
"STREAM-2"
]
}
] | https://clinicaltrials.gov/study/NCT02777580 | STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction | In patients ≥ 60yrs with acute ST-elevation myocardial infarction randomised within 3 hours of onset of symptoms the efficacy and safety of a strategy of early fibrinolytic treatment with half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antit... | STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction | [
{
"description": "Half dose Tenecteplase",
"name": "Tenecteplase",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Metalyse",
"TNKase"
],
"type": "Drug"
},
{
"description": "300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once dail... | [
{
"design_group_description": "Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.",
"design_group_title": "Pharmaco... | [
"Myocardial Infarction"
] | [
"Katholieke Universiteit Leuven"
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "硫酸氢氯吡格雷",
"lang": "CN"
},
{
"name": "Clopidogrel Bisulfate",
"lang": "EN"
},
{
"name": "クロピドグレル硫酸塩",
"lang": "JP"
}
],
[
{
"name": "替奈普酶",
"lang": "CN"
},
{
"name": "Tenecteplase",
"lang": "EN"
}
]... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a29a55e508ad8288e48523ed2ae2dae5",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "STREAM-2"
}
] |
NCT00384618 | [
{
"id_field": "org_study_id",
"id_value": [
"C97-1707"
]
}
] | https://clinicaltrials.gov/study/NCT00384618 | Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study | The ATIC study is a randomised, double- blind, placebo-controlled trial in which the effects of oxidative stress-lowering treatment on vascular function and structure are studied in patients with chronic non-diabetic renal failure who are free from manifest arterial occlusive disease. Participants in the trial were ran... | Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease | [
{
"name": "pravastatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "vitamin E",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Chronic Kidney Disease"
] | [
"Stichting Onderzoek Cancer Center Amsterdam"
] | [
"Bristol Myers Squibb Co.",
"Medical Research Foundation"
] | [
[
{
"name": "普伐他汀钠",
"lang": "CN"
},
{
"name": "Pravastatin Sodium",
"lang": "EN"
},
{
"name": "プラバスタチンナトリウム",
"lang": "JP"
}
],
[
{
"name": "维生素E烟酸酯",
"lang": "CN"
},
{
"name": "Vitamin E Nicotinicate",
"lang": "EN"... | null |
NCT02976194 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-0186"
]
},
{
"id_field": "acronym",
"id_value": [
"CyPov"
]
}
] | https://clinicaltrials.gov/study/NCT02976194 | Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy | Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of ranibizumab. | Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy | [
{
"description": "Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.",
"name": "ranibizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lucentis"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or... | [
"Exudative Age-related Macular Degeneration",
"Polypoidal Choroidal Vasculopathy"
] | [
"Pusan National University Hospital"
] | [
"Novartis AG"
] | [
[
{
"name": "雷珠单抗",
"lang": "CN"
},
{
"name": "Ranibizumab (Genentech)",
"lang": "EN"
},
{
"name": "ラニビズマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CyPov"
}
] |
NCT00740935 | [
{
"id_field": "org_study_id",
"id_value": [
"RB 06.117"
]
},
{
"id_field": "acronym",
"id_value": [
"IVANHOE"
]
}
] | https://clinicaltrials.gov/study/NCT00740935 | Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. | Universal rotavirus vaccination program for infants born in Brest after February 2007, applied by the Centers for Maternal and Infant Health Protection, pediatricians and general practitioners.<br/>Prospective surveillance of hospitalizations for gastroenteritis within the Pediatric Units of Brest University Hospital w... | Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. | [
{
"description": "Vaccination against rotavirus<br/>Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose.",
"name": "Rotateq vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Rotateq"
],
"type": "Biological"
}
] | [
{
"design_group_description": "Cohort of vaccinated infants against rotavirus",
"design_group_title": "1",
"design_group_type": "Other",
"intervention": [
{
"intervention_description": "Vaccination against rotavirus<br/>Three oral doses (2 mL) between 6 to 26 weeks of life with at leas... | [
"Rotavirus Gastroenteritis"
] | [
"University Hospital of Brest"
] | [
"MCM Vaccines B.V."
] | [
[
{
"name": "五价重配轮状病毒减毒活疫苗(Merck & Co., Inc.)",
"lang": "CN"
},
{
"name": "Rotavirus vaccine,live(Merck & Co.)",
"lang": "EN"
},
{
"name": "５価経口弱毒生ロタウイルスワクチン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "IVANHOE"
}
] |
NCT02060370 | [
{
"id_field": "org_study_id",
"id_value": [
"2013-0944"
]
},
{
"id_domain": "NCI CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2014-01908"
]
}
] | https://clinicaltrials.gov/study/NCT02060370 | Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) | The goal of this clinical research study is to learn more about the safety of giving sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which they receive no drug. Researchers want to learn more about the side effects of the drug and the effects of a different dosing schedule. | A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC) | [
{
"description": "Starting dose: 50 mg by mouth daily given for 2 weeks \"on\" followed by 1 week \"off\". 1 cycle is 6 weeks.",
"name": "Sunitinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"SUO11248",
"Sunitinib Malate",
"Sutent"
],
"type": "... | [
{
"design_group_description": "Sunitinib starting dose 50 mg by mouth daily given for 2 weeks \"on\" followed by 1 week \"off\". 1 cycle is 6 weeks.",
"design_group_title": "Sunitinib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"i... | [
"Genitourinary Cancer",
"Kidney Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Pfizer Inc."
] | [
[
{
"name": "苹果酸舒尼替尼",
"lang": "CN"
},
{
"name": "Sunitinib Malate",
"lang": "EN"
},
{
"name": "スニチニブリンゴ酸塩",
"lang": "JP"
}
]
] | null |
NCT00446459 | [
{
"id_field": "org_study_id",
"id_value": [
"24223-A"
]
},
{
"id_field": "secondary_id",
"id_value": [
"03-7915-A"
]
}
] | https://clinicaltrials.gov/study/NCT00446459 | Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. | This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.<br/>On average, increasing the PRA from 0 to 50% specifically in the Washington Organ Procurement Organizatio... | The Highly Sensitized Patients: Effects of Mycophenolate Mofetil (MMF) On Anti-Human Leukocyte Antigen (HLA) Antibody Levels In Patients Awaiting Cadaveric Renal Transplant | [
{
"description": "500mg - 1,000mg, taken PO, twice daily.",
"name": "mycophenolate mofetil (CellCept)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Kidney Failure, Chronic",
"Diabetic Nephropathies",
"Glomerulonephritis, IGA",
"Hypertension, Renal"
] | [
"University of Washington"
] | [
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "吗替麦考酚酯",
"lang": "CN"
},
{
"name": "Mycophenolate Mofetil",
"lang": "EN"
},
{
"name": "ミコフェノール酸 モフェチル",
"lang": "JP"
}
]
] | null |
NCT00788775 | [
{
"id_field": "org_study_id",
"id_value": [
"08-244"
]
}
] | https://clinicaltrials.gov/study/NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to test multi-targeted kinase inhibitors with potent KIT inhibitory activity in this patient po... | A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma | [
{
"name": "Nilotinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"AMN107",
"Tasigna"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.",
"design_group_title": "Nilotinib",
"design_group_type": "Experimental",
"design_group_type_... | [
"Mucosal Lentiginous Melanoma",
"Acral Melanoma",
"Melanoma"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"The Brigham & Women's Hospital, Inc.",
"The General Hospital Corp.",
"Novartis AG",
"Beth Israel Deaconess Medical Center, Inc."
] | [
[
{
"name": "尼洛替尼",
"lang": "CN"
},
{
"name": "Nilotinib Hydrochloride",
"lang": "EN"
},
{
"name": "ニロチニブ塩酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT02525757 | [
{
"id_field": "org_study_id",
"id_value": [
"2014-0722"
]
},
{
"id_domain": "NCI-CTRP-Clinical Trial Reporting Registry",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-01543"
]
},
{
"id_field": "secondary_id",
"id_va... | https://clinicaltrials.gov/study/NCT02525757 | MPDL3280A With Chemoradiation for Lung Cancer | The goal of this clinical research study is to learn about the safety of adding MDPL3280A to standard chemotherapy (a combination of carboplatin and paclitaxel) and radiation in patients with lung cancer.<br/>You are being asked to take part in this study because you have non-small cell lung cancer (NSCLC) that is unre... | DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A | [
{
"description": "1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.<br/>Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.<br/>Group 2: MPDL3280A given with standard chemotherapy, and radiation the... | [
{
"design_group_description": "Participants receive standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period when they receive no chemotherapy or radiation.<br/>Consolidation Phase: After the rest period, participants receive MPDL3280A in addition to chemotherapy for 2 cycles.<br/>M... | [
"Lung Cancer",
"Non-Small Cell Lung Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Genentech, Inc."
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"name": "Paclitaxel",
"lang": "EN"
},
{
"name": "パク... | [
{
"identifier_source": [
{
"code": "ad249e8449d2aea43ade04220aeae252",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "DETERRED"
}
] |
NCT00215137 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00013150"
]
},
{
"id_domain": "Duke legacy protocol number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"5731-04-4R0"
]
}
] | https://clinicaltrials.gov/study/NCT00215137 | Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder | This study will determine the safety and effectiveness of escitalopram (Lexapro)in treating obsessive-compulsive disorder (OCD) symptoms. | Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder | [
{
"description": "Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.",
"name": "escitalopram",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lexapro"
],
"type": "Drug"
},
... | [
{
"design_group_description": "Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.",
"design_group_title": "Open Label Escitalopram 10-20 mg/daily",
... | [
"OCD"
] | [
"Duke University"
] | [
"Forest Laboratories LLC"
] | [
[
{
"name": "草酸艾司西酞普兰",
"lang": "CN"
},
{
"name": "Escitalopram Oxalate",
"lang": "EN"
},
{
"name": "エスシタロプラムシュウ酸塩",
"lang": "JP"
}
]
] | null |
NCT02794766 | [
{
"id_field": "org_study_id",
"id_value": [
"CAAE40334914000005342"
]
}
] | https://clinicaltrials.gov/study/NCT02794766 | Inulin and S. Salivarius Reduce Halitosis | Halitosis associated with tongue coating results from the production of volatile sulfur compounds by bacterial action. The use of prebiotics and probiotics might be useful in treating such condition. The aim of this study was to evaluate the effect of the prebiotic inulin combined with the probiotic Streptococcus saliv... | Inulin and Streptococcus Salivarius Reduce Halitosis Associated With Tongue Coating: A Randomized Clinical Trial | [
{
"description": "Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days",
"name": "Inulin+SS",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Inulin plus Streptococcus salivarius"
],
"type": "D... | [
{
"design_group_description": "Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days",
"design_group_title": "Inulin+SS",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b35... | [
"Halitosis",
"Tongue Diseases"
] | [
"University of Passo Fundo"
] | [
"Coordenação de Aperfeiçoamento de Pessoal de Nível Superior"
] | [
[
{
"name": "菊糖",
"lang": "CN"
},
{
"name": "Inulin",
"lang": "EN"
},
{
"name": "イヌリン",
"lang": "JP"
}
]
] | null |
NCT02571543 | [
{
"id_field": "org_study_id",
"id_value": [
"015/15"
]
},
{
"id_field": "acronym",
"id_value": [
"Ibudelay"
]
}
] | https://clinicaltrials.gov/study/NCT02571543 | Can Ibuprofen Delay Ovulation in Natural Cycle-IVF? | During natural cycle in vitro fertilisation, no gonadotropin stimulation is used to stimulate oocyte production. Ovulation is induced with HCG (human chorionic gonadotropin) and the follicle is retrieved 36 hours later.<br/>In this study the patient in the intervention group will receive Ibuprofen as a study interventi... | Investigation of Ibuprofen in the Delay of Ovulation in NC-IVF (Natural Cycle in Vitro Fertilisation) Therapy With the Objective of Reducing Premature Ovulation and Thus Improving Effectivity (Off Label Use) | [
{
"description": "Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.",
"name": "Ibuprofen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Brufen®"
],
"type": "Drug"
}
] | [
{
"design_group_description": "2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.<br/>Stage 2: 17 patients will be treated either with the l... | [
"Ovulation",
"Ovulation Inhibition",
"Ovulation Inhibition/Drug Effects",
"Pregnancy",
"Fertilization in Vitro/Methods"
] | [
"Insel Gruppe AG"
] | [
"IBSA Institut Biochimique SA"
] | [
[
{
"name": "布洛芬",
"lang": "CN"
},
{
"name": "Ibuprofen",
"lang": "EN"
},
{
"name": "イブプロフェン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Ibudelay"
}
] |
NCT00006244 | [
{
"id_field": "org_study_id",
"id_value": [
"1461.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2011-01313"
]
},
{
"id_field": "secondary_id",
"id_value":... | https://clinicaltrials.gov/study/NCT00006244 | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | This phase II trial studies the effectiveness of melphalan, peripheral stem cell transplantation, and interleukin-2 followed by interferon alfa in treating patients who have advanced multiple myeloma (MM). Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combi... | Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma | [
{
"description": "Given IV",
"name": "melphalan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Alkeran",
"CB-3025",
"L-PAM",
"L-Sarcolysin",
"L-phenylalanine mustard"
],
"type": "Drug"
},
{
"description": "Given SC",
"name"... | [
{
"design_group_description": "Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekl... | [
"Refractory Multiple Myeloma",
"Stage I Multiple Myeloma",
"Stage II Multiple Myeloma",
"Stage III Multiple Myeloma"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "美法仑",
"lang": "CN"
},
{
"name": "Melphalan",
"lang": "EN"
},
{
"name": "メルファラン",
"lang": "JP"
}
],
[
{
"name": "阿地白介素",
"lang": "CN"
},
{
"name": "Aldesleukin",
"lang": "EN"
}
]
] | null |
NCT01942837 | [
{
"id_field": "org_study_id",
"id_value": [
"13-301"
]
}
] | https://clinicaltrials.gov/study/NCT01942837 | Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with chemotherapy.<br/>The purpose of this study is to analyze features of tumor specimens sampled pri... | Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing | [
{
"description": "Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activ... | [
{
"design_group_description": "Administration: 160 mg orally once daily with a 28-day cycle. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.<br/>Dosing: 160 mg orally taken once daily as four 40 mg capsules.",
... | [
"Metastatic Castration-resistant Prostate Cancer"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"MediVation, Inc."
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
]
] | null |
NCT06261502 | [
{
"id_field": "org_study_id",
"id_value": [
"2023-4527"
]
},
{
"id_domain": "Health Canada",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"275882"
]
},
{
"id_domain": "Canadian Institutes of Health Research",
"id_field": "second... | https://clinicaltrials.gov/study/NCT06261502 | Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome | This study focuses on the therapeutic relevance of the endocannabinoid (eCB) system for the treatment of Fragile-X syndrome (FXS), the primary hereditary cause of autism spectrum disorder (ASD). Most individuals with FXS have moderate to severe intellectual disability (ID), and caregivers are mainly concerned about agg... | Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome | [
{
"description": "Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.",
"name": "CBD Oral Solution",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Participants will receive a dose of a placebo... | [
{
"design_group_description": "Participants will start with CBD to stimulate the eCB for 12 weeks, undergo an 8-week washout period, and then receive a 12-week placebo.",
"design_group_title": "CBD First",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33... | [
"Fragile X Syndrome"
] | [
"University of Sherbrooke"
] | [
"Canadian Institutes of Health Research",
"Centre Hospitalier Universitaire de Sherbrooke",
"Jazz Pharmaceuticals Plc"
] | [
[
{
"name": "大麻二酚",
"lang": "CN"
},
{
"name": "Cannabidiol",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CANAX"
}
] |
NCT00620568 | [
{
"id_field": "org_study_id",
"id_value": [
"3170A1-1001"
]
}
] | https://clinicaltrials.gov/study/NCT00620568 | Study Evaluating Multiple Ascending Dose in Schizophrenia Patients | This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder. | An Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder | [
{
"description": "sustained release tablets taken once daily for 14 days",
"name": "SLV-313 SR",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "sustained release tablets taken once daily for 14 days",
"intervention_name": "SLV-313 SR",
... | [
"Healthy"
] | [
"Wyeth AB"
] | [
"Solvay Pharmaceuticals, Inc."
] | [
[
{
"name": "盐酸阿哆嗪",
"lang": "CN"
},
{
"name": "Adoprazine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT06557785 | [
{
"id_field": "org_study_id",
"id_value": [
"HVTN 312"
]
},
{
"id_domain": "DAIDS DOCUMENT ID",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"39019"
]
},
{
"id_field": "secondary_id",
"id_value": [
"39019;HVTN 312"
]
... | https://clinicaltrials.gov/study/NCT06557785 | A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV | This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses ... | A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV | [
{
"description": "To be administered intramuscularly as a split dose",
"name": "CH505M5 N197D mRNA-gp160",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "To be administered intramuscularly as a split dose",
"name": "CH505 TF mRNA-gp160",
... | [
{
"design_group_description": "25 mcg of CH505M5 N197D mRNA-gp160, to be administered as a split dose intramuscularly at weeks 0, 8, and 16.<br/>Followed by:<br/>25 mcg of CH505 TF mRNA-gp160, to be administered as a split dose intramuscularly at week 24.",
"design_group_title": "Group 1 (25 mcg)",
"des... | [
"HIV Infections"
] | [
"National Institute of Allergy & Infectious Diseases"
] | [
"Tasmania Department of Health & Human Services",
"National Institutes of Health"
] | [
[
{
"name": "CH505 TF mRNA-gp160",
"lang": "EN"
}
],
[
{
"name": "CH505M5 N197D mRNA-gp160",
"lang": "EN"
}
]
] | null |
NCT00788112 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000617655"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCSF-077532"
]
},
{
"id_field": "secondary_id",
"id_value": [
"H10367-31833"
]
},
{
"id_field": "secondary_id",
"id_value": [
... | https://clinicaltrials.gov/study/NCT00788112 | Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast | RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.<br/>PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast. | A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast | [
{
"name": "vorinostat",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "protein expression analysis",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"type": "Genetic"
},
{
"name": "immunohistochemistry staining method",
"normalized_... | [
{
"design_group_title": "Vorinostat",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "protein expression analysis",
"intervention_type": "Genetic",
"normalized_interven... | [
"Breast Cancer"
] | [
"The University of California, San Francisco"
] | [
"National Cancer Institute"
] | [
[
{
"name": "伏立诺他",
"lang": "CN"
},
{
"name": "Vorinostat",
"lang": "EN"
},
{
"name": "ボリノスタット",
"lang": "JP"
}
]
] | null |
NCT03300505 | [
{
"id_field": "org_study_id",
"id_value": [
"UMCC 2017.055"
]
},
{
"id_domain": "University of Michigan",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"HUM00130051"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/C... | https://clinicaltrials.gov/study/NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus enzalutamide in patients with metastatic castration resistant prostate cancer. | ARRO-CITO: (UMCC 2017.055) Phase Ib/II Single-Arm Multi-Center Study of IONIS-AR-2.5Rx, a Next Generation Androgen Receptor Antisense Oligonucleotide, in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | [
{
"description": "Given intravenously (IV)",
"name": "ARRx",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"AZD5312"
],
"type": "Drug"
},
{
"description": "Given by mouth (PO)",
"name": "Enzalutamide",
"normalized_type": "3d1aa88261d64c038413723... | [
{
"design_group_description": "Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Da... | [
"Prostate Cancer"
] | [
"Rogel Cancer Center: University of Michigan"
] | [
"National Cancer Institute"
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
],
[
{
"name": "AZD-5312",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "a2420a2aea28e534e0e225834250d09e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "UMCC 2017.055"
}
] |
NCT00753844 | [
{
"id_field": "org_study_id",
"id_value": [
"18-29"
]
}
] | https://clinicaltrials.gov/study/NCT00753844 | Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer | The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer. | Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 | [
{
"description": "Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.",
"name": "URLC1... | null | [
"Esophageal Cancer"
] | [
"Kinki University"
] | [
"University of Tokyo"
] | [
[
{
"name": "HLA-A*2402 Restricted Epitope Peptides Drived From URLC10 Vaccine(Kinki University)",
"lang": "EN"
}
]
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.